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ABSTRACT 
Coronary artery disease (CAD) is one of the leading causes of heart failure (HF). The overall 
aim of this thesis is to describe contemporary epidemiology of post myocardial infarction HF 
including temporal trends, changes in patient characteristics, its determinants and prognostic 
implications, as well as the long-term risk of HF admission. We also examined adherence 
patterns to beta-blocker treatment after acute myocardial infarction (AMI) and subsequent 
implications on outcome using a nationwide myocardial infarction registry. 
The thesis includes four papers. The first paper described the incidence, temporal trends, and 
prognostic impact of HF complicating acute AMI. The second paper investigated the 
incidence, determinants and prognostic implications of HF with normal ejection fraction 
(HFNEF) that occurs in the setting of AMI. The third paper investigated the risk and 
predictors of HF admission among survivors of AMI. Finally, the fourth paper investigated 
the pattern of adherence to beta-blocker treatment in one-year AMI survivors, and assessed 
predictors of better adherence and subsequent implications on long-term all-cause mortality 
and/or HF admissions.  
The incidence of in-hospital HF during an index hospitalization for AMI decreased by 39% 
with an absolute risk reduction (ARR) of 18% over 13 years with more pronounced reduction 
among STEMI (ARR 22%) than NSTEMI (ARR 14%) patients, p<0.001. The use of rapid 
revascularization treatment and evidence-based pharmacologic treatment increased over the 
years (1996-1997 vs. 2008). Patients with clinical HF after AMI had a higher risk for death 
(adjusted HR: 2.09; 95% CI: 2.06 to 2.13). However, mortality was decreasing over time, 
showing the potential for a further decrease with even better treatment strategies.  
HF with normal EF was a relatively less common form of HF in the setting of AMI but its 
occurrence was associated with at least a 3-fold increase in mortality compared to patients 
with NEF and no HF. Interestingly, patients who had evidence of left ventricular systolic 
dysfunction (LVEF <50%) without clinical HF had better long-term prognosis than patients 
with HFNEF, underscoring the importance of clinical findings such as pulmonary rales to 
predict higher risk of mortality complementary to EF. 
Long-term survivors of MI without a previous history of HF remain at risk of late-onset HF 
(LOHF) with in-hospital HF being a strong predictor. Out of 150,566 AMI survivors without 
prior HF, 19.4% (n=29,194) were readmitted due to HF during the study period (2004-2013). 
However, the incidence of LOHF after AMI showed a declining trend over the years which 
largely seems to be related to a decreasing burden of comorbidities and an improved 
evidence-based revascularization strategy and pharmacologic treatment. 
Out of 38,597 one-year AMI survivors, 31.1% were non-adherent to beta-blocker treatment 
one year after the index event. Patients with LVSD (REF) without signs of HF and patients 
with HFREF were more likely to receive beta-blockers at discharge and adhere to treatment 
one year after the index AMI. Better adherence was associated with improved long-term 
outcomes in all patients except in patients with HFNEF. Of note, the long-term prognostic 
advantage seen also in low-risk patients highlights the need for future studies. 
In conclusion, though gains have been made in AMI treatment, the lingering problem of HF 
underscores the importance of interventions at all levels that mitigate its occurrence starting 
from primordial preventive measures, early identification and treatment of risk factors, 
prompt and effective treatment of AMI and implementation of evidence-based secondary 
prevention therapies while ensuring the continuous monitoring of epidemiological trends.  
 
LIST OF SCIENTIFIC PAPERS 
 
The present thesis is based on the following papers, referred to in the text by their Roman 
numerals: 
I. Liyew Desta, MD, Tomas Jernberg, MD, PhD, Ida Löfman, MD, Claes Hofman-
Bang, MD, PhD, Inger Hagerman, MD, PhD, Jonas Spaak, MD, PhD, Hans Persson, 
MD, PhD  
 
Incidence, Temporal Trends, and Prognostic Impact of Heart Failure Complicating 
Acute Myocardial Infarction in the SWEDEHEART registry: A Study of 199,851 
Patients Admitted With Index Acute Myocardial Infarctions, 1996 to 2008. 
 
JACC Heart Fail. 2015 Mar;3(3):234-42.  
 
II. Liyew Desta, MD, Tomas Jernberg, MD, PhD, ClaesHofman-Bang, MD, PhD, Jonas 
Spaak, MD, PhD, Hans Persson, MD, PhD 
 
Heart Failure with normal ejection fraction is uncommon in acute myocardial 
infarction settings but associated with  poor outcomes: a study of 91,360 patients 
admitted with index myocardial infarction between 1998 to 2010. 
 
Eur J Heart Fail. 2016 Jan;18(1):46-53.  
 
III. Liyew Desta, MD, Tomas Jernberg, MD, PhD, ClaesHofman-Bang, MD, PhD, Jonas 
Spaak, MD, PhD, Hans Persson, MD, PhD 
 
Risk and Predictors of Readmission for Heart Failure following a Myocardial 
Infarction between 2004-2013: A Swedish Nationwide Observational Study. 
 
Submitted  
 
 
IV. Liyew Desta, MD, Masih Khedri, MD, Tomas Jernberg, MD, PhD, Pontus Andell, 
MD, PhD, Moman Aladdin Mohammad, MD, Claes Hofman-Bang, MD, PhD, 
David Erlinge, MD, PhD, Jonas Spaak, MD, PhD, Hans Persson, MD, PhD 
  
Adherence to Beta-blockers and Long-term risk of Heart failure and Mortality after 
a Myocardial Infarction: a study of 40,697 patients in the SWEDEHEART registry   
 
Submitted  
  
CONTENTS 
1 INTRODUCTION .......................................................................................................... 7 
 1.1 Historical perspectives .............................................................................................. 7 
       1.1.1 Heart failure (HF) ............................................................................................. 7 
       1.1.2 Coronary heart disease (CHD) ....................................................................... 10 
 1.2 Definition ................................................................................................................. 13 
       1.2.1 Diagnostic criteria .......................................................................................... 13 
       1.2.2 Systolic and diastolic HF ............................................................................... 13 
 1.3 Epidemiology .......................................................................................................... 15 
       1.3.1 The scope of the problem ............................................................................... 15 
       1.3.2 Incidence and prevalence  .............................................................................. 15 
       1.3.3 Morbidity and quality of life .......................................................................... 16 
       1.3.4 Prognosis ........................................................................................................ 16 
 1.4 Pathophysiology ...................................................................................................... 17 
 1.5 Etiologies ................................................................................................................. 19 
 1.6 Heart failure after myocardial infarction ................................................................ 20 
        1.6.1 Incidence and temporal trends of CAD and AMI  ....................................... 20 
        1.6.2 Incidence of HF and/or left ventricular dysfunction (LVSD)...................... 20 
        1.6.3 Ventricular remodeling after AMI ................................................................ 21 
        1.6.4 Clinical characteristics of patients with HF and LVSD after AMI ............. 22 
        1.6.5 Prognostic value of HF after AMI ................................................................ 24 
              1.6.6 Prognostic value of LVSD ............................................................................ 24 
              1.6.7 Prognostic value of HF & LVSD .................................................................. 25 
              1.6.8  HF/LVSD developing and recovering after AMI ........................................ 25 
              1.6.9 Temporal trends of HF and LVSD after AMI .............................................. 25 
              1.6.10 Adherence to secondary preventive therapies ............................................ 26 
         1.7 Pros and cons of observational studies and randomized clinical trials ................ 26    
2 AIMS ............................................................................................................................. 28 
3 MATERIAL AND METHODS ................................................................................... 29 
 3.1 Patient population and registries ............................................................................. 29 
        3.1.1 SWEDEHEART............................................................................................ 29 
        3.1.2 Validity of the register .................................................................................. 30 
        3.1.3 Merging with other national registries.......................................................... 30 
 3.2 Definitions ............................................................................................................... 31 
        3.2.1 Acute myocardial infarction ......................................................................... 31 
        3.2.2 In-hospital heart failure ................................................................................. 31 
        3.2.3 Inhospital HF and LVSD .............................................................................. 31 
        3.2.4 HF readmissions ............................................................................................ 31 
        3.2.5 Assessment of prescription and adherence ................................................... 32 
 3.3 Patients and methods ............................................................................................... 32 
        3.3.1 Paper I & II .................................................................................................... 32 
        3.3.2 Papers III  ...................................................................................................... 32 
        3.3.3 Paper IV ......................................................................................................... 33 
 3.4 Endpoints ................................................................................................................. 34 
 3.5 Choice of variables in regression models ............................................................... 35 
 3.6 Missing variables .................................................................................................... 35 
 3.7 Ethics ....................................................................................................................... 35 
 3.8 Statistics ................................................................................................................... 36 
4 RESULTS  ................................................................................................................... 38 
 4.1 Paper I ...................................................................................................................... 38 
 4.2 paper II ..................................................................................................................... 41 
 4.3 Paper III ................................................................................................................... 44 
 4.4 Paper IV ................................................................................................................... 46 
5 GENERAL DISCUSSIONS ...................................................................................... 50 
 5.1 Major findings ......................................................................................................... 50 
       5.1.1 In-hopital post-MI HF .................................................................................... 51 
       5.1.2 HF with normal EF in the setting of AMI ..................................................... 52 
       5.1.3 Long-term risk of HF after AMI .................................................................... 53 
       5.1.4 Adherence to beta-blockers post AMI and effect on prognosis ................... 54 
       5.1.5 Gender differences ......................................................................................... 55 
 5.2 Monitoring of trends in post-MI HF ....................................................................... 56 
 5.3 Limitations ............................................................................................................... 57 
       5.3.1 Overall limitations .......................................................................................... 57 
       5.3.2 Paper I ............................................................................................................. 57 
       5.3.3 Paper II ........................................................................................................... 57 
       5.3.4 Paper III .......................................................................................................... 58 
       5.3.5 Paper IV .......................................................................................................... 58 
6 CONCLUSIONS ............................................................................................. 59 
7 CLINICAL IMPLICATIONS ............................................................................. 60 
8 FUTURE PERSPECTIVES ............................................................................ 60 
9 SVENSK SAMMANFATTNING ...................................................................... 61 
10 ACKNOWLEDGEMENTS .............................................................................. 63 
11 REFERENCES ..................................................................................................... 66-81 
 
  
  
LIST OF ABBREVIATIONS 
 
ACEI   Angiotensin-converting enzyme inhibitors 
ACS   Acute coronary syndrome 
ARB   Angiotensin II Receptor Blockers 
ARR   Absolute risk reduction 
AMI   Acute Myocardial Infarction 
CABG   Coronary Artery Bypass Graft 
CCU   Coronary-care unit 
CAD   Coronary Artery Disease 
CKD   Chronic kidney disease 
COPD   Chronic obstructive pulmonary disease 
ECG   Electrocardiography  
EF   Ejection Fraction 
HFNEF   HF with Normal EF 
HFREF   HF with reduced EF 
HFPEF   HF with preserved ejection fraction 
HF   Heart Failure 
HR   Hazard ratio 
ICD-10   International Classification of Diseases 
NSTEMI   Non-ST-elevation myocardial infarction 
LOHF   Late-onset HF 
LVEF   Left ventricular ejection fraction 
LVSD   Left ventricular systolic dysfunction 
PCI   Percutaneous Coronary Intervention  
STEMI   ST-elevation- myocardial infarction 
SWEDEHEART Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart 
Disease Evaluated According to Recommended 
therapies 
  7 
1 INTRODUCTION 
1.1 HISTORICAL PERSPECTIVES 
1.1.1 Heart failure 
Heart failure (HF) is a global problem of our time, that has been known since ancient times1. 
The earliest reported case of chronic HF dates back over 3500 years to the remains of an 
Egyptian dignitary who lived under the reign of the 18th dynasty Pharaoh Thutmose III 
(1479–24 BC). On a recent histopathologic examination of the lungs, pulmonary edema due 
to HF was proposed as the likely cause of death2. Hippocrates (467-377 B.C) described 
pulmonary rales and detailed symptoms of HF. He also discussed a rather modern way to 
drain fluid from the chest through a hole drilled in the ribcage.  Galen (c.130 AD – c.210 
AD), viewed the heart as the source of heat and thought that the heart’s primary function was 
to distribute heat to the body. His opinions were to dominate Western thinking for more than 
1500 years3, 4. 
Several centuries had elapsed before William Harvey clearly described circulation and 
provided the basis for understanding the hemodynamic abnormalities in HF in 16285. A few 
centuries later a turning point occurred after the discoveries of Frank in 1895 and Starling in 
1918 (Frank-Starling law) when a more biologically oriented research for regulatory 
mechanisms of heart function was initiated6.  
 
 
“… When edema is gross and 
fails to respond… Southey’s 
tubes constitute a cleaner way of 
removing fluid…” 
Paul Wood. Heart failure. In 
Diseases of the heart and 
circulation. 1957;311  
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Blood-letting and leeches were used for centuries as treatment of HF7. The benefits of 
digitalis were described by Withering in 17857. In the 19th and early 20th centuries, HF 
associated with excessive fluid retention was treated with Southey’s tubes. 
The understanding of HF was significantly advanced in the 1940s and 1960s by the 
introduction of cardiac catheterization 8 which enabled characterization of many forms of 
structural heart disease. In the decades before the 1980s, the changes occurring in HF were 
related to the backward/forward theories and treatment was based on bed rest, inactivity and 
fluid restriction. Digitalis and diuretics constituted the mainstay of pharmacologic treatment 
by then 3.  
The description of Starling Curves9 introduced the idea of myocardial contractility. Despite 
the difficulties in measuring contractility, the prevailing view was that contractility was 
reduced in patients with chronic HF and that increasing it would have a  positive effect10. 
However, most clinical trials of inotropic drugs were stopped prematurely because the agents 
did more harm than good and none had a positive effect on survival 11. Later, cardiac 
glycosides were also found not to improve survival in patients with HF in sinus rhythm 12.  
One important event took place in cardiology in December 1967, when Christian Barnard 
conducted the first orthotopic heart transplant in Cape Town, South Africa. The 1960s was 
also the decade that saw the emergence of LV assist devices (LVADs)13, 14. From the mid-
1970s, the availability of vasodilators provided a means to reduce afterload 15. However, it 
soon emerged that despite the benefits related to their hemodynamic effects, a series of trials 
showed that patients treated with these agents were at greater risk of developing worsening 
HF and mortality than those treated with placebo 16-18.  
In the 1980s, the importance of non-hemodynamic abnormalities in HF were realized, when 
the neurohumoral response to reduced cardiac output was found to have a major adverse 
effect on long-term survival. The neurohumoral response was recognized as a compensatory 
response for short-term hemodynamic challenges like exercise and hemorrhage, which has 
harmful effects when the response is sustained 19-23. In HF, blood pressure and cardiac output 
are reduced over long time periods. Therefore, the neuroendocrine response is chronically 
activated, with deleterious consequences as the persisting increase in catecholamines and the 
renin-angiotensin system (RAS) damages the function and structure of myocytes leading to 
fibrosis. 
  9 
 
Dr Barnard and the first patient who received a heart transplant. 
One important piece of evidence proposing HF to be much more than a hemodynamic 
syndrome came from studies of beta-blockers which, in spite of causing initial worsening of 
hemodynamics, improved prognosis24, 25. As a result of improved pathophysiologic 
understanding of HF, angiotensin converting enzyme inhibitors (ACEIs) and beta-blockers 
were successfully introduced as effective treatments for HF 24-28. Later, mineralo corticoid 
receptor antagonists (MRA)29, 30 and the angiotensin receptor blockers (ARBs) 31, 32 joined the 
group of drugs that counteract neuroendocrine activation. 
The role of implantable cardioverter-defibrillators (ICDs) in preventing arrhythmia related 
mortality in HF patients was established in the beginning of the 21st century although the first 
device was implanted a few decades earlier33. A few years later cardiac resynchronization 
therapy (CRT) was shown to enhance ventricular contractility, diminish secondary mitral 
regurgitation, reverse ventricular remodeling and sustain the improvement in ejection fraction 
(EF) 34, 35 and subsequently became established treatment of HF in appropriately selected 
patients. Other therapeutic technologies are continuously providing new advances in left 
ventricular assistance such as implant-based multi-parameter telemonitoring 36, chronic vagal 
stimulation 37 and cardiac contractility modulation though the available evidence is 
considered insufficient to support guideline recommendations. The electronic revolution has 
enabled cardiologists to monitor heart function at a distance by wireless technologies.  
Furthermore, new therapeutic possibilities for HF are being investigated in the fields of 
molecular biology, genetics and stem-cell therapy with substantial hopes 37.  
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New pharmacological treatments were also introduced in the later years. The PARADIGM -
HF study recently showed a dual angiotensin receptor and neprilysin inhibition (ARNi) with 
sacubitril/valsartan (LCZ696) significantly improved prognosis compared with Enalapril38. 
The same drug is being studied in patients with HF with preserved EF (HFPEF) while other 
ongoing trials are investigating various new classes of drugs developed from advances made 
in the pathophysiological understanding of HF. 
Moreover, the advent of HF clinics has improved adherence and dosing of evidence-based 
treatment while contributing to improved self-care behavior through patient education and 
physical training programs, with subsequent improvement of survival and reduction in HF 
related events 39. 
Indeed, much has happened throughout the history of HF but there is much which remains to 
happen. While modern medicine has come a long way in the treatment of HFREF, HF with 
preserved EF (HFPEF) and acute HF remain two areas with large unmet needs for 
pathophysiological insights and improved therapies. 
1.1.2 Coronary artery disease  
Angina pectoris, the main symptom of coronary artery disease (CAD) was first clinically 
described in the late 18th century 40. The pathogenesis was unknown up until early 19th 
century. Almost a century had passed after the description of angina before pathologists 
recognized the importance of the coronary arteries in its pathogenesis. At the turn of the 20th 
century pathologists related acute myocardial infarction (AMI) with thrombosis in the 
coronary arteries. In the early 20th century, a number of cases of AMI were described and by 
1919 electrocardiography was able to diagnose the disease41. By that time, the recommended 
treatment was total bed rest. In-hospital mortality was close to 40%, and many victims likely 
succumbed to early malignant arrhythmias and pulmonary embolism due to prolonged 
immobilization. The management of AMI constituted these approaches  until the mid-20th 
century42.  
Physiologists were able to characterize pressures in the major vessels and heart chambers of 
animals in the 19th century43. The cumulative effect of their efforts led to the first human heart 
catheterization, performed by Werner Forssman on himself in 1929, which led to a much 
better understanding of cardiac hemodynamics 44 and paved the way for the development of 
coronary arteriography in 195845. These advances were of paramount importance in the 
development of the first revascularization strategy, coronary artery bypass grafting (CABG)46, 
47. 
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Other crucial developments were also taking place during the same time-period. The 
Framingham study was started in 1948 with the collaboration of professionals from different 
disciplines with the goal of understanding the mechanisms behind CAD by analyzing 
lifestyles in the population. Their findings identified high blood pressure and elevated lipid 
levels as definite risk factors. Later, smoking was identified as another major risk factor for 
the development of CAD. The recognition of these risk factors introduced the idea that CAD 
and its complications could be prevented. Educating clinicians and the public about these risk 
factors have led to huge improvements in age-adjusted cardiovascular death rates 42.  
The first major advance in the treatment of AMI came prior to the advent of CABG and 
percutaneous coronary interventions (PCI) in the early 1960s with the development of 
dedicated coronary intensive care unit after Day48 and Brown et al 49 reported their initial 
experiences with the clustering of patients with AMI in special care areas designed for 
continuous monitoring of the electrocardiograms. The in-hospital mortality for MI patients 
was halved with the addition of coronary intensive care units (CCUs). A few years later 
Killip and Kimball performed a study of specialized care for myocardial infarction involving 
250 patients with objectively proved AMI treated in a specially designed, equipped and 
staffed coronary care unit in a voluntary teaching hospital50. To provide a clinical estimate of 
the severity of myocardial derangement, they classiﬁed patients into one of four categories 
recognizing HF as a deleterious complication of AMI: 
1) No heart failure (HF); 2) HF as demonstrated by the presence of basilary rales, an S3 
gallop, and/or elevated jugular venous pressure; 3) Severe HF or frank pulmonary edema; and 
4) Cardiogenic shock. This system later became known as the Killip classiﬁcation, which we 
still use today. Its implementation in practice has since evolved to guide management and 
prognosticate while serving as an important tool for tracking outcomes in clinical research.  
Another major advance took place in 1976 when the fibrinolytic agent, streptokinase was 
used to open acutely occluded coronary arteries by intracoronary infusion 51. The GISSI trial 
showed that intravenous streptokinase reduced early mortality in patients with AMI 52. Soon 
thereafter, the ISIS-2 trial showed that the addition of aspirin led to further reductions in 
mortality53. Subsequently, more potent platelet inhibitors (e.g., P2Y12 and glycoprotein 
IIb/IIIa platelet–receptor blockers) were developed 54. During that era, randomized, controlled 
clinical trials (RCTs) became established approaches for the advancement of effective 
treatments such as ACE-inhibitors55-58, angiotensin receptor blockers 31, beta-blockers 24, 25, 
59-61 and aldosterone blockers 29, 30.  
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Figure 1. Decline in Deaths from Cardiovascular Disease in Relation to Scientific Advances. ALLHAT 
denotes Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, CASS Coronary 
Artery Surgery Study, GISSI Italian Group for the Study of Streptokinase in Myocardial Infarction, HMG-
CoA 1-hydroxy-3-methylglutaryl coenzyme A, ISIS-2 Second International Study of Infarct Survival, MI 
myocardial infarction, NCEP National Cholesterol Education Program, NHBPEP National High Blood 
Pressure Education Program, PCI percutaneous coronary intervention, SAVE Survival and Ventricular 
Enlargement, and TIMI 1 Thrombolysis in Myocardial Infarction 1.42 Used with permission from Nabel EG & 
Braunwald  E.,  N Engl J Med 2012;366:54-6342 
 
The 1960s and 70s heralded the emergence of the field of invasive cardiology. Andreas 
Grüntzig performed the first coronary balloon angioplasty in 1977, a few years after the 
pioneering work of Dotter and Judkins 43. More than a decade later, RCTs demonstrated it to 
be more effective than thrombolysis and paved the way for the era of primary PCI 54, 62. 
Balloon angioplasty was followed by the insertion of baremetal stents, and today, drug-
eluting stents are used together with effective double antiplatelet treatment to prevent 
coronary restenosis63. 
Indeed, notable advances have taken place over the last several decades which have improved 
the prognosis of patients with AMI impressively (Figure 1). However, HF remains a 
common complication after AMI occurring both as early and late complications and causing 
considerable morbidity and mortality. 
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1.2 DEFINITION OF HF 
Heart failure is a common syndrome resulting from a variety of cardiac diseases and is 
characterized by a reduced cardiac output that is unable to meet the metabolic needs of the 
body. According to the 2016 ESC guidelines the diagnosis of HF requires33: 
 the presence of appropriate symptoms, typically breathlessness or fatigue at rest or 
during exertion or ankel swelling and 
 objective evidence of structural and/or functional cardiac dysfunction, resulting in a 
reduced cardiac output and or/elevated filling pressures at rest or during stress with 
accompanying signs (e.g. elevated jugular venous pressure, pulmonary crackles and 
peripheral oedema) 
 In case of doubt, symptom improvement with HF therapy.  
The first 2 criteria should be fulfilled in all cases. HF is a largely clinical diagnosis that is 
based on a careful history and physical examination.  
1.2.1 Diagnostic criteria  
Several standardized diagnostic criteria have been used for the purpose of case ascertainment 
on a large scale to study the epidemiology of HF. However, they lack uniformity64 
contributing to the discrepancies observed in the findings of studies on trends and outcomes. 
The ones used  include the Framingham criteria65, the Boston criteria 66, the Gothenburg 
criteria67 and the European Society of Cardiology criteria68. The European Society of 
Cardiology criteria require objective evidence of cardiac dysfunction 68-71. Altogether, the 
scores are largely similar for the detection of HF 72.  
1.2.2 Systolic and diastolic HF 
After establishing the diagnosis of HF, assessment of the LVEF is made to classify HF into 
HF with preserved (HFPEF) or reduced EF (HFREF). Systolic HF is identified by a reduced 
EF however different thresholds have been used by different groups 73-77. A threshold of 
≥50% remains the most commonly used77-83. Using this threshold, HFPEF constitutes more 
than half of HF cases in the population 84, 85. 
The 2016 ESC guidelines 33, defines HFPEF by the presence of symptoms and/or signs of 
HF, a ‘preserved’ EF (deﬁned as LVEF ≥50% or 40–49% for HF with medium range EF), 
elevated levels of natriuretic peptides and objective evidence of other cardiac functional 
(signs of elevated LV ﬁlling pressure) and structural alterations (left atrial enlargement and 
LV-hypertrophy). For confirmation of the diagnosis, a stress test or invasive assessment of 
LV ﬁlling pressures may be needed.  
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The two entities have distinct structural changes which are also associated with distinct 
functional consequences involving in particular the LV end systolic pressure–volume 
relationship (Figure 2) 86.  
The term ‘diastolic HF’ was ﬁrst used to reﬂect the leading pathophysiological factor 
believed to cause the syndrome - LV diastolic dysfunction. However, patients with ‘systolic 
HF’ were even more likely to have moderate/severe diastolic dysfunction compared with 
patients with so-called ‘diastolic HF’. Nonetheless, progression of LV diastolic dysfunction 
was found to be a major mechanism distinguishing HFPEF.  
There are still signiﬁcant uncertainties surrounding the pathophysiology and treatment of 
HFPEF, leaving clinicians in a dilemma regarding its optimal management. New paradigms 
including a prominent role of co-morbidities, inﬂammation, endothelial dysfunction, and pro-
hypertrophic signaling pathways have been proposed. The disease appears to be 
pathophysiologically distinct and not merely a continuum with HFREF 86. 
 
 
Figure 2: (A and B) Pressure–volume loop 
characteristics in HFPEF (black) and HFREF 
(red) in baseline conditions (A), and in response to 
vasodilators (B). Adapted and reused with 
permission from Eur Heart J.2014;35(16):1022-
1032 86 
 
 
 
 
 
 
 
In addition to etiological  and phenotypic heterogeneity  the prominent contribution of co-
morbidities make understanding the HFPEF syndrome particularly challenging 87.  
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1.3. EPIDEMIOLOGY 
1.3.1 The scope of the problem 
HF has become an important public health problem with increasing prevalence and economic 
burden on societies88, 89. In high income countries, HF is the most common diagnosis in 
hospitalized patients ≥ 65 years. HF carries a prognosis which is  worse than that of most 
cancers37. Understanding the epidemiology of HF remains challenging, despite reports from 
large population-based studies, mostly from developed countries 90-92. The reasons are related 
to difficulties in its diagnosis due to the non-specific nature of symptoms that may result from 
various cardiovascular and non-cardiovascular conditions that lead to impaired cardiac 
function. 
Epidemiological studies have not employed a consistent definition of HF making 
comparisons difficult. The Framingham Heart study employed a clinical definition of HF 
without an objective assessment of ventricular function 93. Other studies have included 
echocardiographic analysis of ventricular function in detailing the prevalence of HF 94.  
1.3.2 Incidence and prevalence of HF 
The incidence of HF varies according to the populations studied and the definitions 
employed, and is dependent on age and sex. The incidence rate is estimated to be 1-4 per 
1000 per year 95, 96. Higher age and male gender are associated with higher incidences. Data 
from the Framingham cohort have shown a doubling in incidence of HF with each decade of 
ageing. Although incidence of HF is approximately one-third lower in general for women 
than men, women comprise about one-half of the HF burden due to their longevity 97. 
Interestingly, women who suffer from a MI are more likely to develop HF than men 97. 
Several common risk factors for HF, including hypertension, valvular heart disease, obesity, 
and diabetes mellitus, are more powerful predictors of HF risk in women than in men 98 . 
The prevalence of HF is approximately 1-2% of the adult population in developed countries 
rising to ≥ 10% among people >70 years of age. It increases with age, and is more common in 
men than in women in those aged >40 and <80 years (Figure 3).  
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Figure 3: Adapted and used with permission from Mozaffarian D, Benjamin EJ, Go AS, et al., on behalf of the 
American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke 
statistics—2015 update: a report from the American Heart Association99 
At the age of 40 years (or at 40 years old), the lifetime risk of development of HF is 1 in 9 for 
men and 1 in 6 for women. In those with a prior history of MI at age 40 years the lifetime risk 
for the development of HF is greater, being 1 in 5 for both men and women. As patients with 
CAD, hypertension and HF itself continue to live longer with better treatment, it is expected 
that the prevalence of HF will continue to rise. Furthermore, changing demography, increased 
prevalence of major CV risk factors such as hypertension, diabetes, and obesity as well as 
progressive chronic kidney disease (CKD) (add to abbreviations), may also contribute to an 
increase in prevalence over time. Worldwide, it is estimated that HF affects more than 38 
million people 37 an increase from 23 million estimated in the 1990s 100. 
1.3.3 Morbidity and quality of life  
Patients with HF are burdened not only by disabling symptoms, but also have high 
prevalence of comorbidities including hypertension, diabetes, atrial fibrillation and chronic 
pulmonary disease. They are also at higher risk of developing thromboembolic complications 
including stroke, MI and venous thromboembolism100-102. Clearly, therefore, patients with HF 
are likely to be dependent on frequent consultations with healthcare services, in both primary 
care and hospital settings. Such dependence exemplifies the demand HF places on health-care 
resources. 
HF has a significant detrimental effect on quality of life which encompasses physical and 
psychological wellbeing, as well as social functioning.  
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Readmissions for HF remain common, with significant quality of life and economic 
repercussions. Multiple hospitalizations, particularly of elderly patients with multiple 
comorbid conditions, are especially common. In patients aged ≥65 years, the 30-day hospital 
readmission rate is approximately 30% 103. Insights from large registries have revealed that 
approximately 20% of patients admitted with acute decompensated HF have no weight loss 
during their hospitalization,104 suggesting the inadequacies of in-hospital management.  
1.3.4 Prognosis 
Reports from the Framingham cohort have confirmed a decrease in long-term mortality with 
symptomatic HF. Nevertheless, the 10-year survival for patients with symptomatic HF 
remains only 20%, with a median survival of 1.7 years for men and 3.2 years for women 90. 
Approximately 50% of patients diagnosed with HF die within 5 years 91. The poor survival 
seen in the Framingham (US) data has also been observed in the European population with 
HF 105. HF mortality increases with age and rises precipitously after 65 years of age. The 30-
day inpatient hospital mortality is 11% in US patients aged ≥65 years admitted with HF 103. 
Indeed, the 65-year age-adjusted and sex-adjusted mortality rate for HF is worse than for 
most common malignancies, including breast and prostate cancer 106.  
1.4 PATHOPHYSIOLOGY 
HF is the clinical syndrome that results from structural or functional abnormalities that impair 
ability of the heart to fill with or eject blood. A patient with HF has decreased cardiac output 
which in turn leads to decreased tissue perfusion. The body thus tries to maintain adequate 
tissue perfusion and compensates to bring mean arterial pressure back to normal using several 
mechanisms including the Frank–Starling mechanism, neurohormonal activation and 
ventricular remodeling. While initially beneficial, the long-term effects of these mechanisms 
serve to worsen HF in a vicious cycle if the adaptation persists107-109. 
Cardiac insults that cause myocardial pressure overload, volume overload, or decreased 
contractility trigger adaptive responses whose purpose is to improve cardiac output and 
maintain blood flow to vital organs. However, when these responses become persistent, they 
lead to the structural and molecular changes that characterize ventricular remodeling. 
Neurohormonal activation in response to decreased cardiac pump function consists primarily 
of increased sympathetic activation (SA) and upregulation of the renin-angiotensin-
aldosterone system (RAS)110 (Figure 4). Plasma norepinephrine (NE), an indirect measure of 
total SA is elevated and is associated with an increased risk of mortality. Increased SA is 
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associated with a number of deleterious effects on cardiovascular function, which can be 
reversed by pharmacologic blockade of sympathetic receptors 111, 112.  
Activations of the Sympathetic and the Renin - Angiotensin - Aldosterone 
systems in heart failure 
 
 
Figure 4: Used with permission from Dorn GW et al (2009), Nat Rev Cardiol 113  
 
Increased SA is accompanied by upregulated activity of the RAAS, causing salt and water 
retention and vasoconstriction114. Angiotensin II (AII) is a potent vasoconstrictor that acts on 
peripheral arterioles. AII production in HF increases afterload, wall stress, and myocardial 
oxygen consumption, ultimately decreasing stroke volume. AII stimulates both SA and 
aldosterone release. In addition, AII stimulation of the myocardium has been associated with 
activation of the fetal gene program, LV hypertrophy, and myocardial fibrosis. Aldosterone is 
a mineralocorticoid hormone that stimulates sodium reabsorption in the distal tubule. When 
combined with AII, the net effect is avid sodium reabsorption in both the proximal and distal 
tubules, contributing to volume overload in HF. Aldosterone also has been implicated in 
proliferation of myocardial fibrosis115. Treatment with neurohormonal blockers that interfere 
with SA and RAAS activity improves survival in patients with HF. 
Natriuretic peptides, atrial natriuretic peptide (ANP), and B-type natriuretic peptide (BNP) 
are released from cardiomyocytes in response to increased atrial and ventricular wall stress. 
The pro-protein proBNP is cleaved into BNP and the physiologically inactive molecule NT-
proBNP. Natriuretic peptides are degraded by neprilysin, a neutral endopeptidase. The 
natriuretic peptides have physiologic functions that counter the effect of sustained SA and 
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RAS activation, including decreasing RAS activity, inducing peripheral vasodilation and 
sodium excretion, and inhibiting myocardial hypertrophy and fibrosis116. Treatment with a 
combination angiotensin-receptor blocker/neprilysin inhibitor (ARNi) reduces the risk of 
death and hospitalization for HF38. Other neurohormonal mediators such as activation of 
arginine-vasopressin system, endothelin-1 and impaired Nitric oxide (NO) system function 
may have significant hemodynamic and ventricular remodeling effects 117-119. 
In summary, the chronic hemodynamic stresses on the heart lead to alterations in the size, 
shape, structure, and function of the ventricle in a process known as remodeling which is 
characterized by myocyte apoptosis, hypertrophy, tissue fibrosis, activation of 
metalloproteinases and increased cardiac expression of cytokines 120-124. An intricate network 
of pathophysiological changes eventually leads to the clinical spectrum of features observed 
in patients with cardiac dysfunction.  
1.5 ETIOLOGIES 
Longitudinal studies 90, 125 provide data relating to the etiologies of HF, and their respective 
contributions at different time periods. In the developed world, CAD and hypertension are the 
principal etiologies in the development of HF in almost 80% of patients with HF126. 
However, the prevalence of CAD in studies of HF vary considerably. Clinical trials and 
population-based studies have reported estimates with large discrepancies 95, 127-131. In the 
initial cohort of the Framingham study, hypertension appeared to be the most common 
underlying condition. However, as time progressed, an increase in the contribution of CAD 
(at the expense of hypertension and valvular heart disease) was noted. Consideration of the 
attributable risk of risk factors for HF and its evolution over time is important for prevention 
88. Other significant causes of HF include idiopathic dilated cardiomyopathy, hypertrophic 
and restrictive cardiomyopathies, and valvular heart disease.  
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1.6 HEART FAILURE AFTER MYOCARDIAL INFARCTION 
1.6.1 Incidence and temporal trends of CAD and AMI  
As outlined above, CAD is one of the leading causes of HF. AMI remains a major clinical 
problem despite reported declines in premature CAD in the developed world. Studies have 
shown decreases in the incidence and severity of acute myocardial infarction (AMI) which 
are partly ascribed to the growing use of coronary artery revascularization procedures and 
better medical treatment 125, 132, 133 though primarily attributable to a reduction in major risk 
factors 134, 135 with a marked decrease in the incidence of ST-segment elevation myocardial 
infarction (STEMI)135, 136 (Figure 5). Effective primary and secondary prevention of coronary 
heart disease is therefore of paramount importance 137. Data from the INTERHEART study 
show that most cases of MI are predictable from what is already known about the preventable 
risk factors 138.  
 
Figure 5. Adapted and used with permission from Yeh RW et al, New Engl J Med 2010;362(23):2155-65. I 
bars represent 95% confidence intervals. MI denotes myocardial infarction, and STEMI ST-segment elevation 
myocardial infarction 135.  
 
1.6.2 Incidence and prevalence of HF and LVSD after AMI  
Over the years, population-based studies 139, 140, registries141-147 and clinical trials148-152 have 
studied changes in the incidence, determinants and prognosis of HF and LVSD after AMI.  
While population-based studies usually report on longer-term follow-up and outcomes post-
AMI, most data on the incidence of in-hospital HF and LVSD originate from clinical trials. 
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While some employed ICD-codes for case ascertainment, probably underestimating the 
incidence of  HF, others utilized evaluation of case-records or patient reviews which is also 
biased by varying definitions of HF and differing study populations 153.  
Hence, the use of different approaches to quantify HF that complicates AMI makes 
comparison of the incidence and prevalence of HF after AMI difficult. However, collectively 
the studies suggest 30-50% of AMI patients have HF at some time following AMI 139-152. 
Patients in clinical trials tend to generally be younger, more often men, often admitted at 
CCUs, with lower incidence of HF on arrival, and higher likelihood of receiving evidence 
based therapies including reperfusion treatments 142, 149, 154. As a result, the reported incidence 
of HF after AMI is lower in trial patients than in epidemiologic studies. Of note, limited data 
are available regarding incidence and prognostic impact of HF with normal EF (HFNEF) in 
the setting of AMI that include detailed structural and functional assessment of diastolic 
function according to current guidelines33, 155. 
Data on the incidence and prevalence of LVSD early after AMI is even more limited partly 
due to the inadequate attention given to it, despite the fact that it is one of the major 
precursors of HF. It is known that imaging evaluations are more likely to be performed in 
patients managed by cardiologists, in younger patients, in patients admitted to CCUs and in 
teaching hospitals, which increases the likelihood of a strong selection bias in the cohorts 
studied. In addition to methodologic issues in echocardiographic LVEF assessment, the 
utilization of other imaging methods and varying cut-offs for defining reduced LVEF 
influence classification of patients, making comparison of reported findings challenging 70, 143, 
144, 148, 150, 152, 155-160 (Table 1). Clinical trials present more complete data on LVEF than do 
epidemiologic studies, however bias related to inclusion criteria in these studies is significant.  
In one prospective population study, the prevalence of LVSD (defined as LVEF ≤30%) was 
found to be approximately 30 per 1000 of the population aged 25 years and older, with 
approximately 50% of those with LVSD being asymptomatic161. The methodological issues 
discussed above account for the discrepancies reported in the incidence and prevalence of 
LVSD after AMI (Table 1). 
1.6.3 Ventricular remodeling after AMI 
A large AMI can lead to changes in the structure of both the infarcted and non-infarcted 
regions of the myocardium. The process of progressive lengthening and secondary volume-
overload hypertrophy occurs in the non-infarcted areas. This alteration affects both the 
function of the ventricle and survival. Acute reperfusion therapy has been shown to result in a 
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reduction in ventricular volume. Both experimental and clinical studies have shown favorable 
changes in the loading conditions of the left ventricle after a long-term therapy with an ACEI 
that prevents progressive ventricular enlargement 162. Acutely, AMI can cause a severely 
dysfunctional ventricle due to massive myocardial ischemia and subsequent necrosis, usually 
presenting as cardiogenic shock. In some patients, acute HF may arise due to mechanical 
complications such as acute ventricular septal defect or papillary muscle dysfunction or 
rupture. Pump dysfunction in the peri-infarct period may alternatively be short-lived due to 
myocardial stunning or ischemia. The underlying cause for the majority of patients 
developing HF is a moderate amount of myocardial necrosis with consequent ventricular 
remodeling163, 164.  
The process of ventricular remodeling starts in the immediate post-infarction period and 
continues slowly thereafter. It consists of ventricular wall thinning in the infract area, 
ventricular chamber dilatation, and compensatory hypertrophy via lengthening of the non-
infarcted portion of the myocardium162. The efficiency of the adaptive process depends on the 
prior health of the non-infarcted myocardium. Diabetic or hypertrophied myocardium may be 
less able to compensate for the area of infarction. Remodeling initially maintains stroke 
volume and pump function but over time these changes become maladaptive leading to 
decreased contractility and a vicious downward spiral culminating in HF 163, 164. The process 
is causally related to neurohormonal activation as discussed in previous sections. The early 
studies on ACEI have shown attenuation of ventricular enlargement with prevention of 
further deterioration of ventricular performance 55, 165. 
1.6.4 Clinical characteristics of patients with HF and LVSD after AMI 
The risk of HF during hospitalization for AMI is increased in elderly subjects, in women, and 
in patients with prior comorbidities such as diabetes, hypertension, pre-existing CAD, stroke 
and renal dysfunction 141, 148, 149, 166. The Global Registry for Acute Coronary Events 
(GRACE) study showed that patients who develop HF in-hospital have a worse prognosis 
than patients who present with HF at admission166. Data from this and another study144 
showed no difference in the incidence of post MI HF between STEMI and non-STEMI 
patients while others reported a higher incidence of Killip class II-IV in patients with 
NSTEMI146. Those with marked LVSD were more likely to have had HF on admission and 
were more likely to develop fatal ventricular arrhythmias. HF is more common after anterior 
MI than after infarction at other sites102. Patients who develop smaller infarcts tend to be 
older with significant comorbidities and have a higher incidence of prior MI with 
subsequently higher likelihood of developing early-onset HF.  
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Table 1: Studies on post Myocardial infarction HF/LVSD 
Study type Period N Age 
mean 
Prior MI LVEF 
cut-off 
Mode of 
LVEF-
assessment 
LVSD HF %-
adm/ 
in-hosp 
Scope of 
analysis 
Trends 
incidence 
of HF 
Population 
based - 
epidemiologic 
 
 
 
         
WHAS 167  1975-1995 6,798  Recurrent - - -  Early Decreasing 
WHAS 139 1975-2001 10,440 72.5 Recurrent - - - 39.9 Early 
onset 
Increasing 
Olmsted 81 1979-1994 1,537  First - - - 36 Early/ late Decreasing 
Olmsted 140 1978-1998 2,171 73 First  - Echo, 
MUGA 
44% 24  All No change 
in survival 
Framingham92  1950-1989 546  - - - - - Late No change 
Framingham168 1970-1999 676 67 First - - - 24 Early/late Increasing 
Canada 169 1994-2000 7,733 >65 First - - - 37 Early/ late Increasing 
HF 
Registries           
French CCU143 1995 2,563 67 18% ≤50% Echo 52% 44  - 
French usic144 2000 2,320 65 18% ≤50% Echo 46% 30.3  - 
NMRI 141 1994-2000 606,500 68.3  - -  20.4 
(+8.6)% 
 - 
GRACE166 1999-2001 16,166 72.5 32% - - - 13 Early - 
CCP 142 1994-1995 42,703 77.3 32.8% ≤40% Not given 26.6% 48.1  - 
EHS ACS 147 2000-2001 10,484 63.4 22.3% - - - 35.2 - - 
Sweden170 1993-2004 175,216 35-84 - - - -  All Decreasing 
Australia 171 1984-1993 4,006 25-64 First - - - 22.4 Early/Late No change 
Clinical trials          - 
BEAT148 1998-1999 3,166 68 28% <40% Echo 31.1% 55.5  - 
InTIME II149 1997-1998 15,078 61 16% - -  23 - - 
VALIANT150 1999-2001 5,566 65.1 24% ≤40% Not given 27.2% 23.1  - 
GUSTO I/IIb/III, 
ASSENT151 
1990-1998 61,041 61.7 - - - - 29.4 - - 
TRACE172 1990-1992 6,676  35% ≤35% Echo 39%   - 
AIRE173 1991-1992 2006 65 - - - -  Early - 
EMIAT157 1991-2001   28.5% ≤40% MUGA 43% 53  - 
ARGAMI-2159 1996   12.6% ≤40% Echo 28% 22  - 
DIAMOND-MI 
158 
1998   36.6 ≤35% Echo 29% 89  - 
MAGIC152 1999-2002 6,213 70 26% <50% Not given  18.7  - 
 CAPRICORN     
174 
 1959 63 30% ≤40% Echo  48  - 
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AIRE, Acute Infraction Ramipril Efficacy;  ARGAMI-2, Argatroban in AMI-2; ASSENT, Assessment of the safety and efficacy 
of a New thrombolyctic; BEAT, Bucindolol Evaluation in AMI trial; CAPRICORN, Carvedilol Postinfarct survival Control in 
LV dysfunction; CCP, Cooperative Cardiovascular Project; CCU, Coronary Care Unit; DIAMOND-MI, Danish 
Investigations of Arrhytmias and Mortality on Dofetilide; EHS, European Heart Survey; EMIAT, European Myocardial 
Infarct Amiodarone Trial; Gusto I, Global Utilization of Streptokinase and tissue-plasminogen activator for Occluded 
Coronary arteries I; GUSTO IIb/III, Global use of Strategies to Open Occluded Coronary Arteries ; GRACE, Global 
Registry of Acute Coronary Events;  InTIME, Intravenous NPA for the treatment of Infarcting Myocardium Early Study; 
MAGIC, Magnesium in Coronaries trial; MUGA, multiple  Gated Nuclear Angiography; NRMI, National registry of MI; 
TRACE,Trandolapril Cardiac Evaluation;  USIC, Unité de Soin’s Coronaries; VALIANT, Valsartan in AMI trial, WHAS, 
Worcester Heart Attack Study 
 
1.6.5 Prognostic value of HF following AMI 
Several studies have demonstrated that HF after AMI increases in hospital mortality 2 to 4-
fold 141, 143, 144, 150, 166, 167. HF has also a detrimental effect on prognosis in the long-term. The 
timing of HF after AMI has been shown to effect prognosis. Development of HF during 
hospital stay is associated with a higher in-hospital mortality than presenting with HF during 
admission166. Post-MI HF also affects morbidity with significantly greater in-hospital 
incidences of re-infarction, stroke and sustained VT/VF compared to those without HF175. 
The appearance of pulmonary rales during hospitalization is one of the signs of an 
unfavorable hemodynamic state 176 and predict worse outcomes 177. Higher Killip class is 
associated with poor long-term outcome177. In the AIRE trial which studied the efficacy of 
Ramipril in AMI patients with clinical HF evidence of HF was defined as at least one of the 
following: evidence of HF one chest radiograph; presence of bilateral rales or auscultatory 
evidence of a third heart sound with persistent tachycardia173.  
1.6.6 Prognostic implication of LVSD after AMI 
Although relatively understudied compared to the prognostic implication of co-existing HF 
and LVSD after AMI, post myocardial infarction LVSD without clinical HF is associated 
with poor outcome. Studies have shown the detrimental effect of LVSD after AMI on both 
short and long-term prognosis, independently of HF150, 178-181. 
1.6.7 Prognostic impact of both HF and LVSD after AMI 
The simultaneous presence of HF and LVSD is associated with even greater risk of morbidity 
and poor short- and long-term prognosis (Figure 10). Killip class and LVSD both predict 
mortality, and their combined presence predict a worse prognosis after myocardial infarction 
153, 182-184 (Figure 6). 
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Figure 6:  Impact of Killip class 
and left ventricular systolic 
dysfunction (LVSD) on 10-year 
mortality. Used with permission 
from Parakh K et al, The 
American journal of medicine. 
2008;121(11):1015-8. 182 
 
 
 
1.6.8 HF/LVSD developing and recovering after discharge from the index AMI 
A patient with post MI in-hospital HF will not necessarily develop chronic HF185. The 
TRACE study showed that in-hospital HF would be transient in approximately 15% of 
patients with major LVSD and 40% of patients without major LVSD186. Other prospective 
studies have shown improvement of the LVEF in up to 30-55% of AMI patients in a matter 
of weeks or months186-188. 
The incidence of late-onset HF is even more uncertain. Data from the Framingham study 
suggested, late-onset HF (one month or more after discharge) may have been reduced by 50% 
while the Olmsted county study reported 41% would develop HF over 6,6 years. Three other 
studies (SAVE56, CAPRICORN 174 and EPHESUS30) reported subsequent HF event varying 
from 11.1% to 15.5% over 15 to 42 months follow up.  
1.6.9 Temporal trends in incidence and prognosis of HF/LVSD after AMI  
There is a paucity of contemporary data on changes in temporal trends in incidence and 
associated short and long-term outcomes of HF after AMI. Most of the studies performed 
over the last 3 decades suggest gradual reduction in the incidence of post MI HF over time 141, 
148, 149, 170, 179, 180, 189, 190 while other studies reported an increasing trend 139, 168, 169, 191, 192. 
Differences in patient population, diagnostic approaches and applied definitions are likely 
reasons for differences in reported findings. 
Studies have also reported conflicting outcomes on mortality trends. While some reported no 
significant reduction140, 190 in one-year mortality in patients with HF after AMI over the years, 
others have reported a declining trend in mortality169, 193. Separation of mortality into in-
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hospital and long-term subsets seems to suggest improved in-hospital outcomes over the last 
decades with unchanged 1-year mortality over time 167, 169. 
Indeed, myocardial infarction and HF are closely related health problems which impose a 
major burden on health care systems worldwide. Hence, it is essential to study how these two 
disease states, that are so closely related but also independent of each other, interplay in the 
modern era of coronary care units, PCI technology and effective medical therapy.  
1.6.10 Adherence to secondary prevention therapies 
Registries have been introduced with the aim of improving quality of care and adherence to 
guideline recommended therapies. Furthermore, the main focus has been improving 
prescription during discharge. However, the intended survival benefits of these medications 
cannot be achieved without sustained therapy. 
Beta-blockers remain a cornerstone in the treatment of patients with CAD, especially post-
MI. Most of the studies that established the positive effect of beta-blockers in ACS pre-date 
the modern reperfusion era but beta-blockers are still widely used194, 195. The place of long-
term treatment especially in low-risk patients is uncertain196. There is a lack of randomized 
clinical trials in the modern reperfusion era investigating the role of beta-blockers in post MI 
patients without LVSD or HF, but a large observational study did not find a lower risk of 
cardiovascular events after ACS in these patients197.  
Thus, studying adherence patterns to beta-blockers and subsequent effect on outcome after 
AMI in real-world patients would give valuable complimentary information in addition to 
giving insights regarding adherence to guideline recommended therapies. 
1.7 Pros and cons of observational studies and randomized clinical trials 
The highest level of scientific clinical evidence stems from prospective, randomized control 
trials (RCTs). Many trials are limited by the specific recruitment of patients using narrow 
inclusion criteria and multiple exclusion criteria, thereby limiting the trial’s generalizability to 
real-world patients seen in practice settings. In addition, large scale RCTs are complex, 
expensive to perform and economic revenue is typically the primary incentive to initiate such 
trials. Consequently, many trials are too small to provide reliable estimates of the risk-benefit 
balance. In general, patients included in RCTs are younger, with fewer comorbidities and a 
lower risk of mortality198.  
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Registry based epidemiologic studies 
High-quality observational studies, based on large-scale registries and adequate statistical 
modelling, provide valuable evidence for the external validity of RCTs making them an 
important complement to RCTs. Furthermore, large-scale observational registries are well 
suited for descriptive studies to investigate associations between patient characteristics and 
risk of disease and mortality.   
Today, studies based on databases, medical records and registries have become extensive in 
epidemiological research.  Even though data collection in register-based studies differs from 
researcher collected data, all persons in a population are available and traditional statistical 
analysis focusing on sampling error as the main source of uncertainty may not be relevant199. 
The main strengths of registry based studies are that data already exists and valuable time has 
passed, study populations are more complete minimizing selection bias and data is 
independently collected. They also have the advantage of studying important clinical 
outcome measures rather than surrogate end-points. Large study populations provide the 
opportunity to study rare conditions and end-points. Their main limitations include the 
possibility that necessary information may be unavailable, data collection is not done by the 
researcher, confounder information is lacking, missing information on data quality and 
truncation at the start of follow-up making it difficult to differentiate between prevalent and 
incident cases and the risk of data dredging199. 
Limitations that are inherent to all observational studies must be considered. Because patients 
are not randomized, it is significantly more problematic to prove causation between exposure 
(e.g. risk factor, treatment) and clinical outcomes of interest.  One important weakness of 
registry studies of treatment effect is that differences between the groups usually generate 
bigger differences in measured “effect” than the real difference between the treatments. When 
a specific treatment is not randomly assigned, other factors such as the preference of the 
physician, the hospital and/or patient may influence the choice, or a concomitant disease 
unknown both to the patient and physician that causes a phenotype for which we are not able 
to adjust.  
The problem with confounders in observational studies is commonly dealt with by using 
multivariate adjusted regression analysis, e.g., logistic regression or cox proportional-hazards 
regression. However, these methods also have their limitations and confounders, especially 
unmeasured confounders, can still result in biased risk estimates – even after adjustments 
using advanced statistical methods. 
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2 AIMS 
OVERALL AIM 
To describe contemporary epidemiology of HF that complicates AMI including changes in 
temporal trends, patient characteristics, determinants and prognostic implications as well as 
the long-term risk of HF readmission and evaluate compliance patterns to mainstay evidence-
based secondary preventive therapies and implications on outcome using a nationwide 
myocardial infarction registry. 
PAPER I 
To study temporal trends in the incidence of HF complicating AMI and its effect on 
prognosis in a large national cohort. 
PAPER II 
To study incidence and predictors of HF with normal EF (>49%) during hospitalization for an 
index AMI and its implications on short and long-term patient outcomes. 
PAPER III 
To study the risk, determinants and temporal trends of late-onset HF (LOHF) and the 
composite event of LOHF and/or death in hospital survivors of AMI in a large national 
cohort. 
PAPER IV 
To study pattern and determinants of adherence to beta-blocker treatment after a first AMI 
and subsequent implications of adherence on risk of all-cause mortality and the composite of 
HF admission and/or death based on status of clinical HF and LV systolic function during 
hospitalization. 
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3 MATERIAL AND METHODS 
3.1 PATIENT POPULATION AND REGISTRIES 
This work is based on data collected in the SWEDEHEART register between 1996 and 2013 
with additional data from the National population register, the National Patient Register 
(NPR), the National cause of death Register and the National register for prescribed drugs 
(NRPD). 
3.1.1 SWEDEHEART 
The Register of Information and Knowledge about Swedish Heart Intensive-Care 
Admissions (RIKS-HIA) database was established as a national quality registry in 1991 
and further improved in 1995 and includes today all Swedish hospitals (n = 72) that 
provide acute coronary care. The registry enrols consecutive patients admitted to a 
coronary care unit or other specialized facility because of symptoms suggestive of an 
acute coronary syndrome (ACS). Information is collected prospectively for more than 100 
variables including baseline characteristics, electrocardiography (ECG) findings, 
examinations, interventions, in-hospital complications, discharge medication and 
diagnoses 200, 201. The variables in RIKS-HIA comply with the international Cardiology 
Audit and Registration Data Standards (CARDS)202.  
The SWEDEHEART (Swedish Web-system for Enhancement and Development of 
Evidence-based care in Heart Disease Evaluated According to Recommended Therapies) 
registry is the largest quality-of-care registry in Sweden and was started in 2009 by 
merging RIKS-HIA with 3 other nationwide cardiac registries. The Swedish Coronary 
Angiography & Angioplasty Registry (SCAAR) includes patients that undergo a 
procedure in any of the 29 cardiac catheterization labs in Sweden. The Swedish National 
Registry of Secondary Prevention (SEPHIA) includes patients under the age of 75 from 
the specialized cardiac outpatient care post-MI. Lastly, the Swedish Heart Surgery 
Registry includes patients undergoing any heart surgery procedure in one of the 8 thoracic 
surgery centres in Sweden. Recently, the trans-aortic valve replacement registry and the 
registry for cardiogenetics have also been added to SWEDEHEART.  
The registry enrols approximately 80,000 cases each year: 30,000 with ACS, 40,000 
undergoing coronary angiography or angioplasty, 7,000 undergoing heart surgery, and 
6,000 who are followed for 12–14 months for secondary prevention after acute coronary 
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syndromes (ACS). The registry is independent of commercial funding and is sponsored 
by Swedish health authorities only. 
The primary aim of the SWEDEHEART registry is to enhance the continuous 
development of evidence-based cardiac care in Sweden, and to measure quality-of-care 
outcome parameters across the country in order to improve the cardiac health of the 
Swedish citizens. It has also increasingly become an important platform for conducting 
valuable research on CAD 200.  
According to the National Board of Health and welfare’s report from December 2015, the 
registry captures close to 100% of patients undergoing angiography, angioplasty, or heart 
surgery and 84% of all AMI patients. While there are some regional differences, most 
regions have a regional coverage of 80-90%.  
3.1.2 Validity of the register: 
To ensure the validity of the data entered in the registry, monitoring visits are performed 
once per year by specially trained monitors who visit different hospitals and compare 
information in hospital charts and the data entries demonstrating a 95% overall 
agreement.  
3.1.3 Merging with other national registries 
Additional data is gathered by merging data from other important quality of care national 
registries. Mortality data were obtained by merging SWEDEHEART with the Swedish 
population register to ascertain vital status and date of death or last date of follow-up. The 
National Patient Registry (NPR)203 was used to obtain data on comorbidities. The registry 
is nationwide and connected to all hospitals in Sweden and collects ICD (International 
Classification of Disease) diagnosis codes linked to all inpatient hospitalizations and 
specialized outpatient visits from 1987 and subsequently. Reporting to the NPR is 
mandatory and departmental reimbursements from the Swedish tax-financed healthcare 
system are wholly based on flat rates from the ICD diagnosis codes. In addition to 
comorbidities, the NPR was also used for cardiovascular endpoints. The National registry 
for prescribed drugs (NRPD) 204 was also used to gather data on previously dispensed 
prescriptions of secondary prevention medications for Paper IV. 
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Data from the components of SWEDEHEART and other national registries were merged 
into a single database with the use of the personal identification number unique to each 
Swedish citizen. 
3.2 DEFINITIONS 
3.2.1 Acute myocardial infarction (AMI) 
In the beginning of the study period (1996-2001), AMI was diagnosed according to 
World Health Organization criteria from 1994 205, 206 combining symptoms, ECG 
changes, or both with an increase in a biochemical marker (mainly creatine kinase [CK]-
MB) exceeding double the upper reference level. From late 2001, the European Society of 
Cardiology/American College of Cardiology/American Heart Association consensus 
document criteria for the diagnosis of AMI were adopted, using mainly troponin T or I 
levels exceeding the 99th percentile in a healthy population together with either typical 
symptoms or ECG-changes. 
3.2.2 In-hospital HF 
In papers I-IV, a clinical definition of HF was used to define in-hospital HF. In-hospital HF 
was defined as the presence of pulmonary rales or administration of intravenous (iv) diuretics 
or usage of iv inotropic drugs, as documented in the RIKS-HIA protocol. Cardiogenic shock 
was defined as systolic blood pressure of ≤90 mmHg for >30 minutes while hypovolemia 
is ruled out in the presence of signs of organ hypoperfusion or if cardiac index was <1,8 
l/min/m2 or if iv inotropes or intra-aortic balloon pump (IABP) were used.  
3.2.3 In-hospital HF and left ventricular systolic dysfunction (LVSD) 
In paper II, we combined in-hospital HF as defined above and LVEF to categorize patients 
based on presence or absence of HF and LVSD assessed by echocardiography and/or, in a 
small minority of patients left ventriculography. Patients were categorized in four groups. 
Those without HF and normal EF ≥50% (NEF), those with signs of HF and normal HF 
(HFNEF), those without HF and reduced EF <50% (REF) and those with HF and reduced 
EF (HFREF).  
3.2.4 HF admissions 
Paper III and IV assessed the risk of late-onset HF (LOHF) after discharge from the index 
AMI. Late-onset HF was diagnosed if a patient was diagnosed as having HF when the record 
for a new hospital admission obtained from the NPR included ICD 10 codes for HF (I50.0-
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I50.9) as principal or secondary diagnosis. The composite event of LOHF or death was 
defined as readmission because of HF as principal or secondary diagnosis or death after 
discharge from the index AMI. A hospital diagnosis of HF in Sweden has been validated 
against ESC criteria for the definition of HF, with a validity of 95% for a principal diagnosis 
and 82% irrespective of position 207.  
3.2.5 Assessment of prescription and adherence 
Paper IV aimed at examining the pattern and associations with long-term outcome of 
adherence to long-term beta-blocker treatment in one-year survivors of AMI. 
Prescription of beta-blocker drugs was determined from the RIKS-HIA protocol if the patient 
was prescribed any beta-blocker drug or not at time of discharge from the index event.  
Adherence was determined as Proportions of Covered days (PDC).  PDC was defined as the 
ratio between the numbers of days covered by the prescription claims of a certain drug, 
divided by the total number of days in the period. As in most previous studies, a threshold 
level for PDC ≥ 80 % was used to classify patients as adherent or non-adherent208, 209. 
 
3.3 PATIENTS AND METHODS 
3.3.1 PAPERS I & II 
Paper I included an unselected cohort of 199,851 patients enrolled in the registry for the 
first time between 1996-2008 who fulfilled the criteria for the definition of AMI.  
Paper II included 90,320 consecutive AMI patients enrolled in the registry between 1998 
and 2010 with known left ventricular ejection fraction (LVEF) assessed by 
echocardiography (99.4%) or LV angiography (0,4%). Patients with unknown LVEF were 
excluded from the analysis. Descriptive analysis of baseline characteristics of patients with 
unknown LVEF was performed to account for differences in patient characteristics between 
those with known and unknown LVEF.  
3.3.2 PAPER III 
In paper III, a total of 177,645 AMI patients who were entered in the SWEDEHEART 
registry for the first time between 2004-2013 were eligible. Among these, 19,483 were 
excluded from the study because of prior history of HF. An additional 7,416 patients were 
excluded due to in-hospital mortality as the main goal of the study was to study LOHF after 
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an index AMI assessed by hospitalization for HF (Figure 7). The final study population 
comprised a total of 150,566 AMI patients. Data on hospitalization for HF after discharge 
from the index AMI admission (up to 31-Dec-2013) were obtained from the national patient 
register and defined as a new hospitalization for HF as outlined above. 
 
Figure 7: Study flow-chart - Patients who were included for the first time in the SWEDEHEART registry 
without prior history of HF and who were discharged alive after the index AMI. Shown are the remaining 
patients after each step of the inclusion criteria.  
 
3.3.3 PAPER IV 
In paper IV, patients admitted to Swedish coronary care units for a first AMI between 2005-
2010 were identified in the SWEDEHEART registry (N=81,023). Patients who died in-
hospital, with previous HF and those with unknown LVEF were excluded. A total of 40,697 
patients comprised the study population for the final analysis. Adherence to prescribed beta-
blockers was determined for one year by merging data from the National register for 
prescribed drugs and its implications on all-cause mortality and the composite endpoint of 
LOHF/death was studied. 
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Table 2.  Summary of the study population, sample sizes and study purposes. 
Studies Study population Sample size Study purpose 
Paper I MI patients enrolled 1996-
2008, SWEDEHEART  
199,851 Describe incidence temporal trends, 
determinants of post MI HF and effect on 
prognosis 
Paper II MI patients with known 
LVEF enrolled 1998-2010, 
SWEDEHEART 
90,320 Describe incidence of HF/LV-dysfunction, 
determinants of HFNEF and differences in 
prognosis 
Paper III MI survivors without prior 
HF enrolled 2004-2013, 
SWEDEHEART  
150,566 Study the risk of HF readmission after 
discharge from index AMI and its 
determinants 
Paper IV First time MI with no prior 
HF surviving hospital course 
enrolled 2005-2010, 
SWEDEHEART 
40,697 
 
Study the pattern of adherence to 
betablockers after discharge, determinants 
and associations with HF readmission and/or 
mortality 
 
3.4   END POINTS 
The incidence of in-hospital post AMI HF was studied in paper I. Paper II included data on 
LVEF in addition to HF. The variables that defined in-hospital HF were obtained directly 
from the RIKS-HIA protocol and were available for nearly all patients. Outcome measures 
used included in-hospital, thirty day, one year and long-term all-cause mortalities. In paper 
III, the endpoints studied were late-onset HF and the composite of late-onset HF and/or all-
cause mortality. In paper IV the primary end-points were all-cause mortality and the 
composite of late-onset HF and/or all-cause mortality which were obtained from the NPR and 
the NDR and were available for all patients.  
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3.5 VARIABLES IN REGRESSION MODELS 
In all studies adjustment was made for several confounders in the logistic regression and cox 
proportional hazard models. For the estimates in the multivariable models to be stable, based 
on empirical data, there should be at least 10 events for each covariate included in the model. 
As there were a large number of outcomes in all studies, this recommendation was never a 
limitation in the number of variables included. 
Adjustments were made for variables that were well-known risk factors, important in-hospital 
clinical characteristics and complications or therapies that could alter the outcome. The ﬁnal 
model included those covariates that remained signiﬁcant in predicting the outcome variable 
(using a p-value <0.05 for assessment of significance). Odds ratios and Hazard ratios were 
calculated with 95% conﬁdence intervals for variables in the models.  
3.6 MISSING VARIABLES  
In SWEDEHEART, variables can have missing data for different reasons, e.g., some 
variables are compulsory to register and some are not. For variables that are not compulsory, 
e.g., smoking status, value of creatinine, weight and height, there is missing data because the 
value has not been registered. For variables that are compulsory, there is often a category 
‘unknown’ – a form of ad hoc imputation that should be treated as missing data (see below). 
Variables in SWEDEHEART have been introduced at different times, therefore data for 
variables which were not a part of the registry at a certain time are missing. Hence, the 
number of missing covariates in the analyses varied. 
In paper I, which mainly is a descriptive study, we presented the number of patients for each 
covariate in Table 1. In papers II-IV analysis was performed in complete cases. To address 
differences in patient characteristics between the study population and patients that were 
excluded from the analysis, a separate analysis that summarizes the characteristics of patients 
who were not part of the analysis is presented in Paper II.  
3.7 ETHICS 
Anonymity was protected by replacing the personal identification number with a serial 
number. In Sweden, quality-of-care registries are parts of the continuing development of 
improved routine healthcare, written consent for patient inclusion in the registries is therefore 
not needed. Patients are informed of quality-of-care registries and have the right not to 
participate, although very few exercise this right. The merging with other registries was 
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approved by the National Board of Health and Welfare. The regional Ethics Committee of 
Uppsala University and the regional Ethics Committee in Stockholm approved the 
studies.  
3.8 STATISTICS 
In baseline characteristics tables, data are presented as numbers and percentages for 
categorical variables. Continuous parametric variables are expressed as means ( standard 
deviation) and medians (IQR). Qualitative data were compared using Pearson’s Chi-square 
test while quantitative data were compared using independent student t-test. In papers I and 
II, the incidence of clinical HF and LVEF/HF categories and estimated proportions of 
patients and their baseline characteristics, as well as mortality over time were evaluated 
by comparing cohorts of patients admitted over 2-calendar year periods. In papers I-III, 
trend tests were performed for the variables where we reported temporal trends using X2 test 
for trend employing the linear-by-linear model. 
In all papers adjustment was made for several confounders in the logistic regression and cox 
proportional hazard models. Unadjusted odds ratios (ORs) with 95% CI were computed using 
univariable logistic regression and adjusted ORs with 95% CI were computed using 
multivariable logistic regression. Unadjusted hazard ratios (HRs) with 95% confidence 
intervals (CIs) were computed using univariable Cox proportional hazard models and 
adjusted HRs with 95% CI were computed using multivariable Cox proportional hazard 
models. Adjustments were made for variables that were well-known risk factors, and in-
hospital clinical characteristics and complications or therapies that could alter the outcome. 
The ﬁnal model included those covariates that remained signiﬁcant in predicting the outcome 
variable (using a p-value <0.05). In paper IV, crude and multivariable adjusted OR with 95% 
confidence intervals were reported. Multivariable adjustment was made using three models.  
In Model 1, OR was adjusted for factors that should affect prescription/compliance to beta-
blockers (potential contraindications). In Model 2, in addition we adjusted for factors that, 
besides HF types, could affect prescription/adherence. In Model 3, we also adjusted for 
gender and socioeconomic factors (country of birth, civil status, educational level and 
income) in addition to factors in Model 1 & 2. 
Endpoint rates were calculated with the Kaplan-Meier estimator and significance testing 
between groups were assessed with the log-rank test. Long-term mortality was presented as a 
Kaplan-Meier plots. 
In paper III, models predictive of the composite of HF readmission/death and death are 
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calculated and presented together with Kaplan-Meier curve for HF readmission as outcome 
variables to handle the competing risk of death.   
In paper IV, interaction tests were performed to calculate p-values for interactions and assess 
differences between subgroups in the association between adherence to beta-blocker 
treatment and long-term outcome.  
Outcome analyses were restricted to complete cases only; no imputations were performed. 
All analyses were performed using SPSS versions 19, 22 and 23 (IBM, Armonk, NY).  
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4 RESULTS  
4.1 PAPER I 
The mean age of the patients increased slightly (70 to 70.9 years) over the study period. 
The proportion of women increased modestly (35 to 37.1%). The burden of comorbidities 
such as diabetes mellitus (21.1% vs. 22.3%) hypertension (32.5% vs. 47%) increased 
across the study period (1996-1997 vs 2008) while the proportion of patients with history 
of prior AMI and previously known HF decreased from 17.8% to 10.6% and 11.7% to 
9.7% respectively. (Table 1, Paper I) 
The incidence of in-hospital HF declined from 46% during 1996-1997 to 28% in 2008 
(RRR of 39% and ARR 18% (p<0.001, X2 test for trend) (Figure 8). Among patients with 
in-hospital HF, the proportion of women increased from 39% to 46% over the years.  
 
 
Figure 8: The incidence of in-hospital HF per 2 calendar year intervals between 1996 to 2008 
This decrease in clinical HF was more pronounced in STEMI (from 50% to 28%) patients 
compared to N-STEMI patients (from 42% to 28%), p<0.001.  
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Figure 9: Trends in the incidence of in-hospital HF by type of MI (STEMI vs N-STEMI) 
Among patients with in-hospital HF, STEMI patients constituted the majority between 
1996-1997 (55.4% STEMI vs. 44.6% N-STEMI) while N-STEMI patients constituted the 
majority in 2008 (35.7% STEMI vs. 64.3% N-STEMI), (Figure 9).  
 
Figure 10: Temporal trend in LV dysfunction(LVEF) over the years in the SWEDEHEART population 
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The proportion of patients with signs of LV-dysfunction declined over the years while 
more patients were discharged with normal LVEF after the index admission in the later 
years (Figure 10). The proportion of HF patients with normal LVEF (EF ≥50%) increased 
from 18% during 1998-1999 to 30% in 2008, whereas the proportion of patients with 
LVEF < 40% decreased from 48% to 44%. Higher Killip class was associated with a 
higher long-term mortality (Figure 11). With Killip I as a reference (HR 1,0): HR 2.5, 
95% CI (2.5-2.6) for Killip II and HR 4.0, 95% CI (3.9-4.1) for Killip III. Patients with 
Killip IV were excluded from the analysis because of their small number and already 
known dismal prognosis. 
 
 
Figure 11: Long-term 
mortality by Killip 
classification during an 
index AMI. Log-rank p 
<0.001. 
 
 
 
Patients above 75 years of age constituted the majority of patients with in-hospital HF 
during the index admission followed by patients 50-75 years of age and <50 years of age 
respectively with a declining incidence of in-hospital HF in both sexes and all age groups.  
Multivariable analysis showed that increasing age and female gender increased the odds 
of in-hospital HF while calendar year decreased the odds.  Risk factors for in-hospital HF 
during hospitalization for an index AMI included history of previous MI, diabetes 
mellitus, hypertension, chronic kidney disease (CKD) and history of known HF. 
The use of PCI showed a progressive increase in both STEMI/LBBB and NSTEMI 
patients while the proportion of patients who were revascularized by acute CABG 
remained relatively unchanged (0.1% vs 0.2%). In STEMI/LBBB patients, the use of 
reperfusion therapy increased progressively- the majority receiving PCI treatment and a 
tiny proportion receiving thrombolysis in the later years of the study period. The use of 
  41 
evidence-based secondary prevention pharmacologic treatment showed a progressive 
increase across the study period. 
The estimated in-hospital, 30-day and 1-year mortality for patients with clinical HF and 
AMI showed a decline across the study period, (P-value <0.001). 
The 1- year risk of death in patients with in-hospital HF after AMI decreased by 7% per 2 
calendar years between 1996 and 2008 (OR 0.93, CI 0.92-0.94), independent of age, gender 
and co-morbidities. Women had a 10% lower mortality than men (OR 0.9, CI 0.8-0.91). 
Long term survival analysis showed a higher mortality for patients with HF compared to 
those without HF (adjusted HR 2.09, CI 2.06-2.13). (Figure 12) 
 
Figure 12: Long-Term Mortality in Patients with and without post-MI HF, Am Coll Cardiol HF 2015;3:234–42. 
Reprinted courtesy of Elsevier. 
4.2 PAPER II  
Among all AMI patients enrolled in the SWEDEHEART registry for the first time between 
1998-2010, data on LVEF was available in 90,320 patients. Echocardiography (99.6%) or LV 
angiography (0.4%) assessments generated these data. Utilization of echocardiography 
increased progressively over time. Patients with known and unknown LVEF were compared 
for differences in baseline characteristics. Patients with unknown LVEF had a higher median 
age (74 years versus 70 years) and the proportion of females was higher (38.2% versus 
34.1%) compared to patients with known LVEF. Comorbidities were more prevalent in the 
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group with unknown LVEF. Patients with unknown EF had higher in-hospital (12.4% vs. 
3.4%), 30-day (14.4% vs. 4.5%) and 1-year mortalities (24.6% vs.10.9%). 
Patients with HF were older (73.3 for patients with HFNEF and 74.4 for patients with 
HFREF) compared to patients without HF irrespective of EF (65.7 years for NEF, 69,1 years 
for REF). The proportion of females was higher among HFNEF patients compared to HFREF 
patients (47% versus 37.5%). Hypertension was more prevalent in HFNEF patients compared 
to HFREF patients: 51.4% versus 43%. Newly diagnosed AF was present among 10.3% of 
HFNEF and 12.9% of HFREF patients. NSTEMI was more common in HFNEF patients 
compared to HFREF patients: 65.7% versus 50.5%.  Co-morbidities such as prior MI, 
previous HF, prior stroke, and renal failure were more prevalent in HFNEF and HFREF 
patients, with slightly higher proportions in HFREF patients (except for COPD which was 
more prevalent in HFNEF patients). The use of reperfusion treatment in patients with STEMI 
or left bundle branch block was lower in HFNEF and HFREF patients, compared to patients 
without clinical HF – irrespective of EF.  
 
Figure 13: Changes in the proportion of AMI patients by LV function and presence or absence of HF over the 
years, Adapted and used with permission from Eur J of Heart Failure (2016) 18,46–53210  
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Analysis of the study population by pattern of LV function coupled with presence or absence 
of clinical HF for each 2-calendar year interval between 1998-2010 showed that HFREF 
decreased from 34.8 % to 17% REF with no HF decreased from 32% to 25.5 %, HFNEF 
remained unchanged (8 %), while NEF without HF increased from 25,5 % to 49,9 % between 
1998-2010 (Figure 13). Among patients with in-hospital HF, incidence of HFNEF increased 
from 18 % to 31 % while that of HFREF decreased from 82 % to 69 % (Figure 14).  
 
 
Figure 14: Temporal trends in incidence of clinical HF by LVEF category over the years. 
 
Table 3: Independent predictors of HFNEF in a logistic regression multivariable 
analysis model  
 
 
Odds ratio  
(95% CI)  
P-value  
Calendar year (2-year 
interval)  
0.88(0.85–0.9)  <0.001  
Age (year)  1.05 (1.04–1.05)  <0.001  
Gender (F/M)  1.3(1.2–1.4)  <0.001  
Hypertension  1.16(1.1–1.2)  <0.001  
Diabetes  1.6(1.5–1.7)  <0.001  
Atrial fibrillation  3.2(2.8–3.6)  <0.001  
COPD  2.1(1.9–2.2)  <0.001  
CKD (eGFR <60 ml/min)  1.8(1.7–1.9)  <0.001 
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Compared to patients with NEF without HF (reference) patients with HFNEF and HFREF 
showed a worse long-term prognosis. HNEF was associated with a higher long-term 
mortality compared to patients with LVSD (REF) without HF (Figure 15).  
 
 
Figure 15: Long-term prognosis 
by LVEF/HF status with their 
respective hazard ratios: NEF 
[1.0], REF no HF (2.2 [2.1- 
2.3]), HFNEF (3.6 [3.5-3.8]), 
HFREF (6.9 [6.7-7.1]). Used 
with permission from Eur J of 
Heart Failure (2016) 18,46–53210 
 
 
 
4.3 PAPER III 
Out of 150,566 AMI survivors without prior HF, 19.4% (n=29,194) were readmitted with 
HF as primary or secondary diagnosis during the study period. Baseline characteristics 
differed significantly among patients who had HF readmission and those who did not. 
Patients with LOHF/death were older, more often women and with higher burden of 
comorbidities such as DM, hypertension and CKD compared to patients who did not 
develop late-onset HF. In-hospital HF was more prevalent in patients with LOHF. The 
utilization of statins, PCI and CABG was lower in those who developed LOHF during the 
study period compared to those who did not develop LOHF (Table I, paper III).  
Risk profile of patients changed across the study period comparing the cohorts of 2004-2005 
and 2012-2013 with decreasing prevalence of CKD (31.9% vs. 24.1%), prior stroke (9.4% vs. 
7.6%), prior AMI (16% vs. 8.5%), and in-hospital HF (31.3% vs.18.7%), while the 
proportion of hypertension (40.5% vs. 49.5%), COPD (4.9% vs. 6.4%) and NSTEMI (59.4% 
vs. 65.8%) increased and the prevalence of DM (21.1% vs. 21.5%) remained relatively 
unchanged. The utilization of revascularization treatment and evidence based pharmacologic 
treatments increased.  
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Figure 16: The risk of late-onset 
HF and the composite event of 
late-onset HF/death over 10 
year period 
 
 
 
 
Increasing number of known co-morbidities was associated with a higher risk of LOHF. 
Compared to patients who had no identified risk factors, the risk of LOHF after AMI 
increased by increasing number of comorbidities: with one risk factor, HR 1.9 (CI 1.9-2.05), 
with 2 risk factors, HR 3.3, (CI 3.1-3.4), with 3 or more risk factors, HR 5.5, CI (5.3-5.7), p-
value <0.001.  
The cumulative risk of developing LOHF at 1-year, 2- year and 5-year were 11.4%, 14.6% 
and 21.8% respectively.  The corresponding figures for the composite event of LOHF/death 
were 16.6%, 22.4% and 35.8% respectively (Figure 16). The risk of developing LOHF within 
2 years after discharge decreased from 15.5% to 14.4% between the cohorts included in 
2004-2005 and 2010-2011, p <0.001 (Figure 17).  
 
Figure 17: The 2-year risk of 
LOHF by 2 calendar-year 
interval: Reference 2012-13; for 
2004-05 HR 1.2 (95% CI 1.1-
1.2) for 2006-07, HR 1.1 (95% 
CI 1.04-1.1), for 2008-09 HR 
1.09 (95%CI 1.01-1.2) and for 
2010-11 HR 1.06, (95% CI 
1.01-1.1)  
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The risk of LOHF showed a declining trend over the study period (2004-2005 vs. 2012-2013) 
after adjustment for baseline characteristics and clinical factors such as in-hospital HF, atrial 
fibrillation and type of AMI (STEMI/NSTEMI). 
Increasing age, male gender and STEMI were associated with an increased risk of LOHF. In-
hospital HF increased risk of LOHF by 2-3-fold. Comorbidities increased the risk of LOHF 
significantly. Calendar year was associated with a lower risk of LOHF/death. 
Compared to patients with NEF without HF, the risk of HF readmission was much higher for 
patients with HFNEF (by four to five-fold) and patients with HFREF (by almost ten-fold). 
Patients with HFNEF showed a higher risk of HF readmission compared to patients with REF 
without HF (p <0.001) (Figure 18).  
 
 
Figure 18: The risk of late-onset HF 
by LVEF/HF status HF: Reference 
NEF without HF: HR 9.5, (CI 9.1-9.8) 
for HFREF, HR 4.3 (CI 4.1-4.6) for 
HFNEF, HR 3.3 (CI 3.2-3.4) for REF 
without HF.  
 
 
 
 
 
4.4 PAPER IV 
Between October 2005 and December 2010, 71,638 patients with their first AMI were 
enrolled in the registry. After excluding patients who died in-hospital, with previous history 
of HF and with unknown LVEF a total of 40,697 patients remained for the final analysis. The 
proportion of patients by status of in-hospital HF and LVEF categories were: NEF without 
HF in 55.1% (n=22,405), REF without HF in 25.7 % (n=10,481), HFNEF in 7.6 % (n=3,082) 
and HFREF in 11.6 % (n=4,729). Patients with HFNEF and HFREF were older. The highest 
proportion of women was seen in patients with HFNEF. Comorbidities such as diabetes, 
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hypertension, CKD were more prevalent in patients with HFNEF and HFREF compared to 
REF and NEF. At time of admission, 25.6 % of all AMI patients were already on beta-
blockers. 
Beta-blockers were prescribed to 90.7% (n=36,869) of all AMI patients at discharge. Patients 
with REF without HF and HFREF were more likely to receive beta-blockers during 
discharge, while patients with HFNEF were less likely to receive treatment with beta-
blockers compared to patients with NEF without HF. The likelihood of beta-blocker 
prescription was higher in patients with REF compared to patients with HFREF.  These 
findings were consistent after adjustment for potential contraindications for beta-blockers 
(Model 1).  
Among one year survivor AMI patients, 68,9% (n=26,595) reached the threshold level for 
adherence (PDC ≥ 80 %) for long-term beta-blocker treatment. Compared to patients with 
NEF without HF, patients with REF without HF were more likely to reach the adherence 
level. Patients with HFNEF were less likely to reach the threshold for adherence.  
Multivariable analysis showed that socioeconomic factors such as being married/cohabiting, 
higher educational level and clinical factors such as hypertension, STEMI and 
revascularization treatments (PCI and CABG) were associated with better adherence to beta-
blocker drugs while higher odds of non-adherence was seen in patients with increasing age, 
low income level, non-married/non-cohabiting, COPD, prior stroke, prior cancer, bleeding, 
dementia, peripheral arterial disease and being on dialysis treatment as well as known relative 
contraindications such as heart rate <60/min and high grade AV-block during hospitalization.  
The 2-year and 4-year cumulative risks for the composite of LOHF or death were lower for 
patients who were adherent to beta-blocker treatment compared to patients who were non-
adherent (5.4% vs. 8.5% and 13.8% vs. 20.3% respectively). Patients with both HF and 
LVSD (HFREF) showed the highest cumulative risks in both groups followed by patients 
with HFNEF, REF without HF and NEF without HF respectively. 
Adherence to beta-blocker treatment was associated with a reduction in all-cause mortality 
and the composite of LOHF/death in both the crude and adjusted analysis in all AMI patients. 
These findings remained consistent even in the subgroup analysis with the exception of 
patients with HFNEF where statistical significance was not reached in the adjusted analysis 
though a trend towards favourable association was seen (Table 4). Interaction tests showed 
significant p-values (<0.05) for all cause-mortality and non-significant p-values (>0.05) for 
the composite end-point indicating that the association between adherence to beta-blocker 
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treatment and all-cause mortality does differ between the LVEF subgroups (normal LVEF vs 
reduced LVEF irrespective of status of HF).   
Long-term survival analysis showed favourable prognostic associations between adherence to 
beta-blocker treatment and the long-term risk of LOHF/death for all LVEF/HF as shown by 
survival curves that continue to diverge after 3 years (Figure 19A-D).  
 
Table 4: Adherence to beta-blockers among one year survivors of AMI and 
associations with all-cause mortality and the composite of LOHF/all-cause mortality 
 
  All patients 
(N= 38,597) 
NEF 
(N= 21,777) 
REF 
(N= 9.927) 
HFNEF 
(N= 2,795) 
HFREF 
(N= 4,098) 
Death      
Crude 0.55 (0.52-0.66) 0.62 (0.55-0.69) 0.49 (0.43-0.55) 0.59 (0.49-0.71) 0.50 (0.44-0.57) 
Adjusted 0.79 (0.73-0.85) 0.84 (0.75-0.95) 0.70 (0.61-0.80) 0.90 (0.74-1.10) 0.73 (0.63-0.85) 
Combined      
Crude 0.65 (0.62-0.69) 0.66 (0.60-0.73) 0.59 (0.54-0.65) 0.63 (0.55-0.73) 0.66 (0.59-0.73) 
Adjusted 0.86 (0.81-0.91) 0.88 (0.80-0.98) 0.77 (0.69-0.85) 0.86 (0.74-1.02) 0.87 (0.78-0.98) 
 
Combined = LOHF or death; Adjustments were made for: age, sex, diabetes, hypertension, CKD, prior stroke and 
drugs (ASA, ACE/ARB, Statins, B-blocker on admission), performed PCI or CABG during hospitalization, 
other antiplatelet/anticoagulant at discharge, and adherence to other drugs during first year (ASA, ACE/ARB, statins). 
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Figure 19A-D: Long-
term risk of 
LOHF/death for the 
four LVEF/HF 
categories by status of 
adherence to beta-
blocker treatment  
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5 GENERAL DISCUSSION 
5.1 MAJOR FINDINGS 
The incidence of acute post MI HF decreased by 39% (an absolute risk reduction of 18%) 
over the study period with more pronounced reduction among patients with STEMI (ARR 
22%) than N-STEMI (ARR 14%). 
 Despite declines in the incidence of HF complicating acute MI with declining in-hospital, 
30-day, and 1-year mortality, HF was associated with a 2-fold greater risk for death in the 
long-term compared with patients without HF after AMI. Simply put, we learned that if and 
when HF complicates acute MI, even if manifested only by basilar rales, prognosis worsens 
markedly. 
HF with normal EF is relatively less common in the setting of AMI. However, the proportion 
of patients with HFNEF increased from 18% to 31% among patients with in-hospital HF 
mainly due to a decline in the incidence of LVSD without HF and HFREF. Patients with 
HFNEF were more likely to have more comorbidities compared to patients without HF 
irrespective of EF.  
The occurrence of HFNEF carries a poor short- and long-term prognosis with at least a three-
fold increase in long-term all-cause mortality compared to patients without HF irrespective of 
LVEF. Among AMI patients with clinical HF, the ones with the highest risk of mortality are 
those who exhibit evidence of both HF and LVSD, i.e. patients with HFREF. 
LOHF is a common late complication after AMI occurring in almost one out of five AMI 
patients within 5 years after discharge with certain risk for underestimation given the 
methodology we used for case ascertainment. Patients with LOHF were older and with a 
higher burden of comorbidities. Increasing burden of comorbidities was associated with 
higher risk of LOHF. The crude overall risk of LOHF shows a small but clearly decreasing 
trend after an index AMI over time which seems to be related to a decreasing burden of 
comorbidities and an improved acute treatment. 
The prescription of beta-blockers after AMI is high in Sweden with close to 91% of AMI 
patients receiving prescription during discharge from the index admission. However, nearly 
one out of three one year survivors were non-adherent to beta-blocker treatment one year 
after the index AMI. 
Patients with REF and no signs of HF and HFREF were more likely to receive beta-blockers 
at discharge in our cohort which is encouraging and in line with guideline recommendations. 
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Patients who did not develop HF and had normal LVEF during hospitalization were more 
likely to discontinue beta-blockers at 1 year while patients with REF had the highest 
likelihood to adhere to beta-blocker treatment. 
Adherence to beta-blocker treatment was associated with improved long-term outcomes in 
AMI patients except in patients with HFNEF. The favorable long-term prognostic effect in 
patients with NEF without HF is of particular interest and challenges the lingering uncertainty 
regarding the indication for long-term treatment beta-blocker treatment after AMI in low-risk 
patients. 
5.1.1 In-hospital post-infarction HF 
Over the last several decades, important changes have taken place in the epidemiology of MI. 
Population studies have shown declining burden of the coronary risk factors such as total 
cholesterol, blood pressure and tobacco smoking, while diabetes and BMI increased 
signiﬁcantly with a net reduction in risk factors which subsequently is reflected by a decline 
in the incidence and case-fatality rate of AMI 136. Besides, a number of advances in 
cardiovascular medicine have conferred reduced mortality for patients with AMI over the 
past 50 years. The advent of the coronary care unit has afforded specialized care with 
possibilities for lifesaving monitoring. Reperfusion therapy has led to reductions in infarct 
size and mortality, and several medications have been shown to be lifesaving. All these 
factors have likely influenced the already complex and multifaceted association between HF 
after MI and mortality.  
Changes have also occurred in the epidemiology of HF after MI, with a decline in its 
incidence and a change in the case mix according to left ventricular dysfunction, 
characterized by an increasing proportion of HF cases presenting with HFPEF, for which 
treatment benefits are less established 193.  
It is also highly likely that improvements in the treatment of AMI have led to a larger number 
of survivors. In survivors of AMI, these treatments result in a reduction in the extent of 
myocardial injury and greater myocardial salvage. To the contrary, others who could have 
died previously may now survive, but with significant myocardial damage. The net 
consequences of these effects on the risk of early and late-onset HF after AMI is uncertain 211. 
The findings of Paper I reflect most probably the net effect of all the advances mentioned 
above and changes in patient characteristics over the years and are consistent with those of 
other recent studies 96, 212-214.   
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Over the years, the diagnostic criteria for AMI has changed, with increasingly sensitive 
biomarkers being used in the later years. Many patients diagnosed to have AMI to date were 
previously diagnosed as unstable angina. Although the incidence rates of AMI and 
subsequent post-MI HF has probably been altered by the use of sensitive biomarkers, the 
decline in the incidence of HF in our study showed a rather smooth progressive decline, 
suggesting other explanations, such as more frequent use of effective evidence-based 
treatments and changes in the burden of risk factors. The larger decline of HF in STEMI 
patients as compared to patients with NSTEMIs also speaks for a true overall temporal 
decline in the incidence of HF after AMI. Thus, the decline in post MI HF observed in our 
study could be a reflection of changes in ascertainment of AMI, decreased severity on 
presentation, as well as advances in the management of AMI215. These evolutions in 
determinants of the incidence and prognosis of HF after MI point to the need for the 
continuous assessment of contemporary trends of post MI HF and its current prognostic role. 
It appears that previous estimates are now outdated because they do not reflect the 
aforementioned changes in the epidemiology of MI, and HF complicating MI, in the 
population. 
5.1.2 HF with normal EF in the setting of AMI 
Heart failure and LVSD are not synonymous181. Some patients will remain asymptomatic 
despite suffering major left ventricular damage. Previous studies reported that 30-50% of 
patients who develop HF will do so without LVSD, mitral regurgitation, or arrhythmias 82, 148. 
While LVSD is assessed objectively, the diagnosis of HF remains subjective with varying 
threshold for diagnosis among physicians. Both LVSD and HF may occur early or develop 
late and both may recover 186-188.  
The findings of Paper II showed that evidence of HFNEF was present in a proportion of AMI 
and when it occurred was associated with poor short-term, intermediate and long-term 
prognosis though slightly better than patients with HFREF. 
Several studies have shown that Killip class and reduced LVEF are predictors of poor long-
term outcome153, 173, 177, 182-184 which is consistent with the findings of our study. The 
pathogenesis of HFNEF after AMI is not well described. Activation of cardiac peptides 216 
and the RAS has been suggested as contributors 217. Studies have shown doppler 
echocardiographic signs of elevated filling pressures in these patients218.  
Paper II also showed a higher burden of comorbidities such as hypertension, diabetes and 
other atherosclerotic manifestations in patients with HFNEF compared to patients that did not 
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develop in-hospital HF after AMI. As cardiovascular disease is suggested to be a continuum 
of events 219,  the increased burden of comorbidities might eventually progress to overt CAD 
with increased susceptibility to an acute loss of even relatively small amounts of cardiac 
muscle and subsequent development of HF.  
As the optimal management of these patients is not known, mechanistic studies that shed 
light on new insights in the pathophysiology and therapies of this distinct phenotype of HF 
are warranted. 
The coexistence of clinical signs of HF and LVSD (HFREF) is associated with the worst 
long-term prognosis. Although with better long-term prognosis compared to patients with 
patients with HFREF and HFNEF, our study confirmed also a substantially increased long-
term mortality in patients with LVSD without signs of HF. This finding confirms the findings 
of previous studies150, 181, 182. As evidence-based treatment is available for these group of 
patients, early identification, triaging and initiation of pharmacologic and device therapies as 
appropriate improves their long-term prognostic outlook. 
5.1.3 Long-term risk of HF after AMI 
Besides heightened risk of mortality, other major non-fatal cardiovascular events such as 
recurrent MI, arrhythmia, stroke, and HF occur more frequently among survivors of the acute 
event. However, the risk for cardiovascular events among MI survivors is not uniform. 
Factors such as the patient's baseline characteristics, infarct extent and complications as well 
as the use of medications and procedures, have been shown to influence prognosis 101, 102.  
The occurrence of LVSD with or without HF after AMI depends on factors, such as recurrent 
myocardial ischemia, infarct size, ventricular remodeling, stunned myocardium, mechanical 
complications and hibernating myocardium 162, 185. While in-hospital HF is usually related to 
infarct size, mechanical complications, or myocardial stunning, the development of late-onset 
HF is mainly related to progressive myocyte loss, hibernating myocardium, and ventricular 
remodeling 220.  
Our study showed that LOHF was a common late complication after AMI. Patients with in-
hospital HFREF had the highest risk of LOHF/death followed by patients with HFNEF and 
REF without HF respectively. Independent predictors of HF include in-hospital HF, 
increasing age, history of hypertension, history of prior MI, and diabetes. Although the 
utilization of revascularization treatment and pharmacologic treatments in AMI patients 
improved over time, their use was lower among patients who developed LOHF during 
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follow up. Similar findings have been reported by previous studies 175. This is particularly 
of concern as these treatments have been shown to improve long-term outcomes 
significantly 174, 221, 222. The explanations behind the underutilization of potentially life-
saving treatments in this group of patients are not well described and could be 
multifactorial. Advanced age, concern for potential side effects such as hypotension and 
worsening renal failure or unawareness of current standards of care, or non-clinical factors 
such as patient gender or geographic limitations to timely access optimal treatment could be 
among the reasons that may impact management decisions. 
LOHF after MI is a serious complication because of a several-fold increase in the risk of 
death 56, 101, 102. Hence, a better understanding of the predictors of LOHF in long-term MI 
survivors would be helpful to identify high-risk patients more likely to benefit from 
implementation of more aggressive preventive measures. The importance of optimizing the 
availability and effective utilization of such strategies in high risk patients need to be 
underscored. 
The mainstay of HF therapy today remains reactive treatment for established and 
symptomatic disease. However, the burden of HF on our societies will continue to grow until 
effective primary and secondary prevention strategies are adopted and employed, along with 
increased awareness of lifestyle choices that can modify risk factors for developing HF 223. 
This is the basis of the staging concept of HF. Hence, our finding underscores the importance 
of identifying at risk patients and treating them aggressively to prevent the development of 
HF by preventing overt CAD and subsequent MI 224. 
5.1.4 Adherence to beta-blockers post AMI and effect on prognosis 
Clinical trials have demonstrated that selected pharmacotherapies reduce cardiovascular 
mortality 225, 226. How their projected survival impact real-world patients is less known, in 
part because of variations in drug adherence. Quality improvement initiatives have mainly 
focused to improve inpatient administration of appropriate drugs during hospitalization for 
the index AMI at hospital discharge.  
Studies have demonstrated the association between better adherence and long-term clinical 
outcomes among patients hospitalized with acute coronary syndromes 227, 228.   
While in general pharmacologic non-adherence could be deemed as a risk for unfavourable 
outcome, whether it applies to patients who receive beta-blocker drugs without strong 
evidence supporting it is unknown. Patients with NEF without HF and patients with HFNEF 
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belong to such a category.  It is unclear if non-adherence to beta-blocker treatment in those 
patients implied increased risk for poor long-term outcomes making it difficult to make 
proper judgment. 
Our study showed that adherence to beta-blocker treatment was associated with improved 
long-term outcomes in all AMI patients except in patients with HFNEF. Similar findings 
have been reported by previous studies 227-230. The favorable long-term prognostic effect in 
patients with NEF without HF is of particular interest and challenges the uncertainty 
regarding the indication for long-term treatment in this subset of patients and calls for well-
designed randomized trials to address the ambiguity. 
The role of adherence to drug specific effects on long-term survival benefits has been 
questioned, in part because prognostic benefits may be the result of "healthy adherer" 
behavioral factors more so than to specific pharmacological benefits 231. Yet, other 
investigators have reported findings that demonstrated the importance of class-specific drug 
effects as mediators of favorable long-term prognostic implications of better adherence 
beyond the “healthy adherer” behavioral attributes 232. 
Non-adherence is also related to increased risk of hospitalization and cost 233. Hence, given 
the huge impact of HF readmissions both on patients as well as health care systems, working 
on strategies that ensure better adherence to beta-blocker treatment and other secondary 
prevention therapies could contribute towards better outcomes that includes HF related 
events. 
5.2 GENDER DIFFERENCES 
Paper I showed that the incidence of in-hospital post MI HF is approximately one-third lower 
for women than men. As in previous studies, women who suffer from a MI showed a higher 
risk of developing HF than men 97. However, their long-term prognosis seems to be better 
than their male counterparts. Post MI HF showed an increasing trend among women over the 
years. Their relative proportion was also higher among patients with HFNEF. Female gender 
was strong predictor of HFNEF together with comorbidities such as diabetes mellitus, 
hypertension, AF, and chronic kidney disease. Women were less likely than men to undergo 
measurement of left ventricular function as the group with unknown LVEF was 
overrepresented by elderly patients who are more often women and with higher burden of 
comorbidities. Previous studies have shown underutilization of appropriate diagnostics 
particularly in women which in turn could lead to undertreatment as most studies on the 
treatment of HF include only patients with REF 234.  
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Patients with LOHF and those with LOHF or death were older, more often women and with 
higher burden of comorbidities. However, female gender was associated with a lower risk of 
LOHF and the composite event of LOHF/death after adjustment for background factors. 
There was no statistically significant gender difference with regards to adherence to beta-
blocker treatment. 
Women have been hugely underrepresented in HF  trials of left ventricular dysfunction with 
the proportion of randomized patients in the major trials ranging from 0% to 32% 97. Nearly 
half of the population hospitalized with HF constitute HF with preserved EF. With women 
having more often HF with preserved EF than men, less CAD as the underlying cause of their 
HF, being older and exhibiting hypertension, diabetes and AF 235, improvement in survival in 
women with HF might be expected to be less marked than men. Most studies on the treatment 
of HF include only patients with HFREF largely excluding patients with HFPEF 234. 
Although women have a lower incidence of HF after AMI, their proportion is increasing 
steadily warranting a special attention especially in future studies that elucidate 
pathophysiologic insights and novel therapeutic strategies. 
5.3 MONITORING OF TRENDS IN POST-MI HF 
As cardiovascular disease is regarded as a continuum of events 219, AMI patients both with 
and without in-hospital HF have a higher risk of developing chronic heart failure and death. 
With improved MI management and medical therapy to combat neurohormonal activation, 
HF now spans a wide spectrum of disease, ranging from acute decompensation to a chronic 
asymptomatic state. Our findings highlight the fact that HF after AMI is still a common 
occurrence and we will continue to see this complication despite the changes in the 
epidemiology of acute coronary syndromes. 
Given the magnitude of AMI and evolving approaches to manage it, continued monitoring of 
these trends remains of considerable clinical and public health importance. Moreover, 
readmissions because of HF are common and remain the main driving factor to the huge 
economic burden related to HF. Thus, studying readmission rates related to HF after AMI and 
predictors of late-onset HF after AMI is of crucial importance. 
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5.4 LIMITATIONS  
5.4.1 Overall limitations 
In observational studies one cannot rule out the possibility of selection bias and residual 
confounding. It is important to be aware that the register does not include the entire AMI 
population 236. Elderly AMI patients with multiple comorbidities and mostly female are likely 
to receive care outside of CCUs and hence not be included in the registry. This circumstance 
decreases the external validity of our findings237. 
A proportion of the patients in the studies have missing data on some of the variables. 
Patients with missing data are known to have higher mortality and, therefore, their exclusion 
from analyses might have produced biased results. All analyses are performed with complete 
cases and imputations were not performed. However, imputations performed in other studies 
based on the SWEDEHEART register has not showed a different result from the primary 
analyses and therefore we don’t believe this would be a major limitation. In paper I, we 
presented the number of patients included in the analysis for most of the variables. In paper 
II, we summarized characteristics of patients with missing LVEF data and presented 
differences compared to the study population. Lastly, in all papers, several statistical tests 
were used, which increases the risk of associations occurring by chance.   
5.4.2 Paper I 
A clinical deﬁnition of HF was used to identify patients with in-hospital HF which has its 
own limitation due to the non-specific nature of physical findings. However, pulmonary rales 
in the setting of AMI are shown to have high sensitivity to predict an unfavourable 
hemodynamic state and worse outcomes 176, 177. A similar definition was used by other studies 
166, 173, 238. Moreover, our criteria also included the use of IV diuretic agents or IV inotropes 
which increases sensitivity but may also lower speciﬁcity. HF at admission could not be 
distinguished from HF which develops during hospital stay restricting the possibility to 
further explore differences in clinical characteristics and outcome. 
5.4.3 Paper II 
The diagnosis of HF based on any criteria is prone to misclassification. It is obvious that 
dyspnea and pulmonary findings could be explained by other cardiovascular and non-
cardiovascular factors such as obesity and COPD. This may hold true for some patients in the 
present study. COPD was seen more often among patients with HFNEF than patients without 
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HF. However, more than 85% of patients with HFNEF did not have any history of COPD, 
suggesting misclassification was not a major problem.  
Although LVEF may be reduced in the acute setting, it recovers in a substantial proportion of 
patients within a few months. As HFNEF and HFREF are traditionally used in the setting of 
chronic HF, the use of the terms in the setting of acute HF associated with AMI could be a 
point of discussion. Our findings may not be generalizable to other non- hospitalized 
populations and hence one should be aware of differences in clinical settings. Other studies 
which investigated the clinical and prognostic implications of acute HF with preserved EF 
post AMI have also used similar approaches 148.  
5.4.4 Paper III 
Less severe HF not requiring hospitalization could have been missed as the development of 
HF in this study required hospitalization, which may have contributed to a relatively lower 
incidence of LOHF. A hospital diagnosis of HF in Sweden has been validated against ESC 
criteria for the definition of HF, with 82% of the HF cases in the hospital discharge register 
classified as having a definite HF according to the ESC definition 207.  Other studies have 
shown administrative codes to be highly specific for cardiovascular diagnoses and risk factors 
239. In any case, what we risk mainly is under diagnosing HF. Hence the findings of this study 
remain valid with several implications in understanding the complex interaction between MI 
and HF. 
5.4.5 Paper IV 
As is true for observational studies, we are restricted to explore fully the influence of 
unmeasured confounders. Meanwhile, the observed effect of better adherence reinforces the 
findings of randomized and observational studies regarding the effect of beta-blockers after 
AMI on long-term outcomes.   
We are also unable to account for brand, dosage administered, or continued use of drugs. As a 
result, this will remain an inherent limitation. It is known that dosage of beta-blockers used 
constitute an important aspect of beta-blocker treatment as under-dosage of beta-blockers is a 
common problem 240, 241. Furthermore, we cannot be certain whether a patient actually took 
the medication despite drug refill. As drug prescription in Sweden only covers 3 months at a 
time, if patients do not refill, one can assume a higher possibility of discontinuation in the 
majority of patients. 
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6 CONCLUSIONS 
 A marked decrease was found in the incidence of HF complicating AMI between 
1996 and 2008. However, HF continues to worsen the early-, intermediate-, and long-
term adverse prognostic risk after AMI. The observed declining trend in the incidence 
of HF and mortality indicates the potential for further decline with further 
improvements in therapeutic strategies. 
 Killip classiﬁcation helps identify a high-risk group for whom speciﬁc therapies need 
to be targeted. Patients with a higher Killip class after AMI (i.e., Killip class ≥II) 
likely require triage to a higher level of care to prevent adverse outcomes. 
 Heart failure with NEF is a relatively less common form of HF in the setting of AMI. 
Nonetheless, its relative proportion is increasing and its occurence carries a poor 
short- and long-term prognosis. 
 Long-term survivors of MI without a previous history of HF remain at risk of late-
onset HF. The risk of LOHF over time seems to show a declining trend mainly related 
to a decreasing burden of comorbidities and an improved treatment of AMI over time. 
 The prescription of beta-blockers as secondary prevention medications after AMI is 
high in Sweden. However, a significant proportion of MI survivors discontinue beta-
blockers one year after the index event. Patients with LVSD without HF and HFREF 
were more likely to receive beta-blockers at discharge. Adherence to beta-blocker 
treatment was associated with improved long-term outcomes except in patients with 
HFNEF where the effect is less obvious.  
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7 CLINICAL IMPLICATIONS 
Though progress has been made in AMI treatment, the lingering problem of HF underscores 
the importance of prompt and effective revascularization and pharmacologic treatments to 
salvage myocardium at risk and inhibit the development of in-hospital HF. Although we 
notice encouraging trends, our findings highlight the important fact that HF after AMI is still 
a common occurrence and we will continue to see this complication despite the changes in 
the epidemiology of acute coronary syndromes. 
Our findings emphasize also the benefits of LV function assessment and vigilance on clinical 
signs of HF to risk stratify patients after AMI as they are at higher risk of late-onset HF and 
death after discharge. Moreover, our findings give insight regarding the need for devising and 
implementing strategies that improve adherence to guideline recommended secondary 
prevention therapies. 
8 FUTURE PERSPECTIVES 
The epidemiology and treatment of AMI is evolving continuously. The burden of HF on 
society is predicted to grow underscoring the need for effective primary and secondary 
preventive strategies. AMI, which is the dominant precursor of HF can be prevented from 
occurring in most patients138.  To further improve the demonstrated encouraging trends by 
our results, a continuous effort to identify potential areas of intervention to reduce the risk of 
HF after AMI is needed.  First, health systems need to intensify their effort in informing and 
empowering citizens to adopt healthy life styles to mitigate the burden of risk factors. 
Second, improving access to health care that facilitates the early detection as well as initiation 
and optimization of effective treatment in patients with established risk factors to prevent 
evolution to CAD is required. Third, more effort need to be made to diagnose and treat both 
AMI and post MI HF earlier with existing interventions while undertaking further research to 
find new interventions.  
The understanding of pathophysiological mechanisms has introduced several paradigms 
which transformed the treatment of HF over the last several decades109. However, there is still 
a need for a continued effort in understanding undiscovered pathophysiologic mechanisms in 
the different phenotypes of HF to open new doors for effective therapeutic approaches. This 
is particularly true in patients with HF with preserved EF and acute HF. This should go hand 
in hand with quality improvement initiatives for monitoring of evolving trends and the 
evaluation of implemented interventions to enhance the continuous development of 
evidence-based cardiac care. 
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9 SVENSK SAMMANFATTNING 
Hjärtsvikt är en allvarlig sjukdom med 5-års överlevnad på c:a 50%. Kranskärlsjukdom är en 
huvudorsak till hjärtsvikt. Övergripande målet för denna avhandling är att beskriva förekomst 
av hjärtsvikt efter hjärtinfarkt, både som akut komplikation vid hjärtinfarkten samt som sen 
komplikation i form av återinläggning för hjärtsvikt eller död. Vidare analyserades 
tidsmässiga trender i förekomst av hjärtsvikt, förändringar i patienternas bakgrund, 
behandling och riskfaktorer och deras prognostiska betydelse. Dessutom, användning och 
följsamhet till behandling med betablockerare som sekundärprevention studerades och om 
bättre följsamhet gav förbättrad långtidsprognos. För avhandlingen analyserades data ur det 
nationella kvalitetsregistret för akut kranskärlssjukdom, SWEDEHEART. 
Arbete 1 studerade 199,851 hjärtinfarktpatienter inlagda för hjärtinfarkt mellan år 1996 och 
2008. Arbete 2 ägnades att studera 90,320 patienter 1998 till 2010 avseende betydelsen av 
klinisk svikt och systolisk vänsterkammardysfunktion med fokus på hjärtsvikt med normal 
systolisk funktion (EF >50%). Tredje arbetet studerade 150,566 patienter utan tidigare 
hjärtsvikt som överlevde sin hjärtinfarkt 2004 till 2013 avseende risken för framtida död eller 
återinläggning för hjärtsvikt och dess riskfaktorer. Sista studien beskrev 40,697 patienter år 
2005-2010 och ordinerad behandling av betablockerare och följsamhet till denna året efter 
hjärtinfarkt i relation till förekomst av initial hjärtsvikt och hjärtfunktion samt fortsatt 
prognos. 
Förekomsten av hjärtsvikt i sambandmed infarkt minskade med 39% (ARR 18%) över 13 år. 
Minskningen var stor både vid ST-höjnings- och icke-ST-höjnings-infarkt men var störst hos 
patienter med ST-höjning. Användningen av revaskularisering (PCI) och evidens-baserad 
farmakologisk behandling ökade under studietiden. Hos patienter som utvecklade hjärtsvikt 
på sjukhuset sågs sjunkande mortalitet både på sjukhuset (19% vs 17%), samt inom 30 dagar 
(23% vs 17%) och 1 år (35% vs 31%) mellan 1996 och 2008. De patienter som skrevs ut med 
påvisad hjärtsvikt på sjukhuset hade en betydligt ökad risk för död över tid jämfört med 
patienter utan hjärtsvikt (justerad HR: 2.09; 95% CI: 2.06 to 2.13). 
Andra studien visar att hjärtsvikt med bevarad vänsterkammares EF (VKEF) är en relativt 
ovanlig form av hjärtsvikt i det akuta infarktsammanhanget och förekommer i c:a 8% av alla 
hjärtinfarktpatienter. Bland patienter som utvecklade hjärtsvikt vid infarkten ökade andelen 
med bevarad EF från 18% 1998–99 till 31 % 2008, tillståndet är vanligare hos äldre patienter 
och kvinnor. Vidare är hypertoni, diabetes, kronisk njursvikt, förmaksflimmer och KOL 
starka prediktorer. Hjärtsvikt med bevarad EF ökar risken för långtidsmortalitet minst 3 
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gånger jämfört med patienter med normal EF utan hjärtsvikt och var också associerad med 
betydligt högre risk jämfört med patienter med nedsatt VKEF utan klinisk svikt. Patienter 
med nedsatt VKEF och klinisk hjärtsvikt har sämst prognos jämfört med övriga 
infarktgrupper uppdelade efter VKEF och klinisk hjärtsvikt.  
Hjärtinfarktpatienter har ökad risk att utveckla hjärtsvikt senare. Utav 150,566 patienter som 
inkluderades I SWEDEHEART registret mellan 2004 och 2013 blev 19,5% (n=29,194) 
återinlagda p g a hjärtsvikt någon gång efter utskrivning. Den kumulativa risken för hjärtsvikt 
1 år, 2 år och 5 år efter utskrivning var 11.4%, 14.6% and 21.8%. Patienter med klinisk 
hjärtsvikt med nedsatt VKEF redan på sjukhuset har den största risken följd av patienter med 
bevarad VKEF och klinisk svikt, nedsatt VKEF utan svikt och bevarad VKEF utan svikt. 
Resultatet visar också sjunkande trend för återinläggning p g a hjärtsvikt över tid vilket 
bedöms bero på minskat antal sam-sjukligheter och ökad användning av PCI och annan 
evidensbaserad farmakologisk behandling.  
I fjärde arbetet analyserades 40,697 patienter med förstagångs-hjärtinfarkt, utan tidigare 
hjärtsvikt och med känd VKEF som överlevt akut hjärtinfarkt. Följsamhet till betablockad 
studerades under första året efter utskrivning. Det visade sig att 90,7% (n=36,869) erhöll 
beta-blockad vid utskrivning vilket är högt jmf med andra motsvarande länder. I följsamhets-
analysen inkluderades patienter som överlevde första året (n=38,597) efter utskrivning och 
där visade det sig att 31,1% inte har varit följsamma till beta-blockad behandling. Patienter 
med nedsatt VKEF med eller utan klinisk hjärtsvikt visade högst sannolikhet att vara 
följsamma, medan patienter med bevarad VKEF med eller utan klinisk hjärtsvikt hade lägre 
följsamhet. Vid 4 års uppföljning efter infarkten sågs en association med lägre risk för 
återinläggning på grund av hjärtsvikt, och död hos de infarktpatienter som varit följsamma till 
behandling. 
Hjärtsvikt efter hjärtinfarkt är vanligt med minskande förekomst över tid, troligen som effekt 
av bättre hjärtinfarktbehandling och förändringar i riskfaktorer. Hjärtsvikt har en fortsatt 
allvarlig prognos även vid bevarad VKEF. Förskrivning av betablockad som 
sekundärprevention är hög oavsett hjärtfunktion och hjärtsvikt men följsamheten är c:a 70%, 
högst dock hos patienter med hög risk där det förefaller gå betydligt bättre om man är 
följsam. Sammantaget är det fortsatt viktigt att uppmärksamma nedsatt hjärtfunktion och 
kliniska tecken på hjärtsvikt vid hjärtinfarkt. 
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